haloperidol has been researched along with Disease Models, Animal in 516 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 63 (12.21) | 18.7374 |
| 1990's | 70 (13.57) | 18.2507 |
| 2000's | 158 (30.62) | 29.6817 |
| 2010's | 191 (37.02) | 24.3611 |
| 2020's | 34 (6.59) | 2.80 |
| Authors | Studies |
|---|---|
| Bagli, J; Bogri, T; Voith, K | 1 |
| Klitgaard, H; Matagne, A; Talaga, P | 1 |
| Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
| Devambatla, RKV; Kumar, MM; Rao, VS; Sekhar, KV | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
| Brennan, J; Carrick, T; Denny, RA; Feenstra, RW; Graf, R; Grauer, SM; Greenfield, A; Grosanu, C; Kowal, DM; Kruse, CG; Lai, M; Marquis, KL; McCreary, A; McFarlane, GR; Navarra, RL; Neut, Mv; Núñez-García, S; Pausch, MH; Pruthi, F; Reinders, JH; Robichaud, AJ; Rotella, DP; Sullivan, K; Zhang, J | 1 |
| Carrick, T; Feenstra, R; Kowal, DM; Kruse, CG; Lai, M; Marquis, KL; Pausch, MH; Reinders, JH; Robichaud, AJ; Rotella, DP; van der Neut, M; Yan, Y; Zhang, J; Zhou, P | 1 |
| Bajpai, M; Banerjee, A; Bhateja, DK; Gandhi, MN; Gharat, LA; Gudi, GS; Gullapalli, S; Gupta, PK; Khairatkar-Joshi, N; Patil, S; Pawar, MY; Sangana, RR | 1 |
| Bojarski, AJ; Bucki, A; Kazek, G; Kołaczkowski, M; Partyka, A; Pawłowski, M; Satała, G; Siwek, A; Wesołowska, A; Zagórska, A | 1 |
| Cao, X; Chen, Y; Lan, Y; Liu, BF; Liu, X; Qiu, Y; Xu, X; Zhang, G; Zhang, J; Zhang, Y; Zhao, S | 1 |
| Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Bucki, A; Chrzanowska, A; Czopek, A; Drop, M; Głuch-Lutwin, M; Kołaczkowski, M; Partyka, A; Pawłowski, M; Pękala, E; Siwek, A; Struga, M; Wesołowska, A; Zagórska, A | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Cheng, J; Fan, L; Liu, R; Tan, L; Wang, H; Wang, S; Yan, W; Yu, J | 1 |
| Hirakawa, T; Kimura, H; Kurimoto, E; Yamada, R | 1 |
| Galvão, BO; Lages, YV; Landeira-Fernandez, J; Maisonnette, SS; Rosseti, FP | 1 |
| Alin, C; Balbine, KN; Eglantine, KW; Guillaume, CW; Hervé Hervé, NA; Jorelle Linda, DK; Léa Blondelle, KD; Roland, RN; Simon Désiré, GN; Simplice, FH | 1 |
| Albalawi, AE; Alsharif, I; Anwar, F; Babalghith, AO; Baokbah, TAS; Chauhdary, Z; Farrukh, M; Khalid, S; Khayat, RO; Panichayupakaranant, P; Saleem, U; Shah, MA; Vargas-De-La-Cruz, C | 1 |
| Ardashov, OV; Arefieva, AB; Gorina, DS; Izyurov, AE; Kotliarova, A; Kulikov, AV; Lastovka, AV; Pavlova, AV; Podturkina, AV; Rogachev, AD; Salakhutdinov, NF; Sidorova, Y; Tolstikova, TG; Volcho, KP | 1 |
| Havas, L; Lőke, J; Maglóczky, Z; Papp, P; Szocsics, P | 1 |
| da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI | 1 |
| Kitagawa, K; Nagai, T; Yamada, K | 1 |
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
| Hussain, A; Hussain, S; Ramirez, N; Sumaya, IC; Villarreal, S | 1 |
| Ahmad, B; Anwar, F; Chaudary, Z; Raza, Z; Saleem, U | 1 |
| Alhakamy, NA; Anwer, MK; Bhattamisra, SK; Choudhury, H; Lim, WM; Md, S; Radhakrishnan, AK; Safian, NH; Shahzad, N; Shak, AT; Xi, LW | 1 |
| Carratalá-Ros, C; Correa, M; Martínez-Verdú, A; Pardo, M; Salamone, JD | 1 |
| Babinska, Z; Bucolo, C; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Fedotova, J; Giurdanella, G; Iannotti, FA; Kratka, L; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Platania, CBM; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT | 1 |
| Melo-Thomas, L; Müller, CP; Schwarting, RKW; Tonelli, LC; Wöhr, M | 1 |
| Cheng, N; Li, A; Qi, F; Sun, B; Wang, S; Wang, Y; Wang, Z; Zhao, L | 1 |
| Makiguchi, A; Okada, T; Shioda, K; Suda, S | 1 |
| Ahmad, B; Akhtar, MF; Anwar, F; Ismail, T; Nazir, S; Saleem, U; Sanawar, M | 1 |
| Babinska, Z; Hammer, T; Horska, K; Karpisek, M; Kotolova, H; Micale, V; Prochazka, J; Ruda-Kucerova, J; Stark, T | 1 |
| Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z | 1 |
| Déciga-Campos, M; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Villafán-Gutiérrez, R | 1 |
| Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J | 1 |
| Ihme, H; Melo-Thomas, L; Schwarting, RKW | 1 |
| Blanco-Hernández, Y; Espinosa-Juárez, JV; López-Muñoz, FJ; Mena-Valdés, LC | 1 |
| Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC | 1 |
| Blobaum, AL; Boutaud, O; Conn, PJ; Dickerson, JW; Fulton, MG; Kent, CN; Lindsley, CW; Loch, MT; Niswender, CM; Rodriguez, AL; Rook, JL; Stillwell, KJ | 1 |
| Alves, CO; de Oliveira, AR; Magalhães, MS; Waku, I | 1 |
| Aiba, A; Funato, H; Koebis, M; Kushima, I; Miyoshi, C; Mori, D; Nakao, K; Ozaki, N; Saito, R; Yanagisawa, M | 1 |
| da Silva, RCB; de Toledo Simões, JG; Dos Santos Bioni, V; Henrique, E; Ramos, AC; Rosenstock, TR; Siena, A; Varga, TG | 1 |
| Bonora, M; Castellazzi, M; Giorgi, C; Ingusci, S; Marchi, S; Patergnani, S; Perrone, M; Pinton, P; Previati, M; Pugliatti, M; Simonato, M; Wieckowski, MR; Zucchini, S | 1 |
| Harishankar, N; Husain, GM; Kazmi, MH; Potnuri, AG; Reddy, KP; Suresh, P | 1 |
| Haleem, DJ; Samad, N | 2 |
| Abubakar, OK; Akintunde, JK | 1 |
| Alves, ND; Bessa, JM; Correia, JS; Machado-Santos, AR; Mateus-Pinheiro, A; Morais, M; Patrício, P; Pereira, J; Pinto, L; Sousa, N | 1 |
| Bondi, CO; de la Tremblaye, PB; Free, KE; Greene, AM; Kline, AE; Lajud, N | 1 |
| Adjei, S; Amoateng, P; Karikari, TK; Kukuia, KKE; Nyarko, AK; Osei-Safo, D | 1 |
| Adjei, S; Amoateng, P; Bekoe, EO; Karikari, TK; Kombian, SB; Kukuia, KKE; Osei-Safo, D | 1 |
| Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Kawase, H; Matsuda, T; Nakazawa, T; Takuma, K; Tanabe, W; Taruta, A; Tsukada, S | 1 |
| Abbott, GW; Alachkar, A; Civelli, O; Hamzeh, AR; Lee, SM; Sanathara, N; Wang, L; Wang, Z; Xu, X; Yoshimura, R | 1 |
| Cao, D; Kang, B; Meng, Y; Ning, H; Wang, H; Xie, S | 1 |
| Melo-Thomas, L; Schwarting, R; Tonelli, LC; Wöhr, M | 2 |
| Amano, I; Obi, K; Takatsuru, Y | 1 |
| Bondi, CO; Cheng, JP; Free, KE; Kline, AE; Leary, JB; Meyer, EA; O'Neil, DA | 1 |
| He, GF; He, GZ; Lei, K; Li, J; Li, XP; Liu, D; Liu, YN; Ren, XH; Zhang, CL | 1 |
| Nirmal, S; Vikhe, S | 1 |
| Chang, KC; Chen, CN; Soung, HS; Tseng, HC; Wang, MH | 1 |
| Engelhardt, KA; Marchetta, P; Melo-Thomas, L; Schwarting, RKW | 1 |
| Capuani, C; Corsi, M; Harada, A; Kimura, H; Suzuki, H; Suzuki, K; Ugolini, A | 1 |
| Aderibigbe, AO; Ajayi, AM; Ben-Azu, B; Eneni, AO; Iwalewa, EO; Umukoro, S | 1 |
| Gupta, S; Patel, RK; Sharma, AK; Wardhan, N | 1 |
| Boeckers, T; Hengerer, B; Nespoli, E; Rizzo, F; Schulze, U | 1 |
| Ali, J; Baboota, S; Dang, S; Kumar, S; Nigam, K | 1 |
| Abotsi, WKM; Ekuadzi, E; Kumbol, VW; Woode, E | 1 |
| Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S | 1 |
| Gill, KM; Grace, AA; Sonnenschein, SF | 1 |
| Hisatsune, A; Kajiwara, Y; Katsuki, H; Kurauchi, Y; Matsuda, K; Seki, T; Yamada, T; Yoshimaru, Y | 1 |
| Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB | 1 |
| Bussey, TJ; Hailwood, JM; Heath, CJ; Phillips, BU; Robbins, TW; Saksida, LM | 1 |
| Dal Mas, C; de Almeida Campos, MR; Hayashi, MAF; Marins, LAN; Martins, LG; Monte, GG; Mori, MA; Nani, JV; Tasic, L | 1 |
| Barroca, NCB; Brandão, ML; Colombo, AC; da Silva, NT; de Oliveira, AR; Guarda, MD; Reimer, AE | 1 |
| Lin, JR; Nakagawasai, O; Nemoto, W; Odaira, T; Onogi, H; Sakuma, W; Srivastava, LK; Takahashi, K; Tan-No, K | 1 |
| Battini, T; Braga, L; Carloni, P; Celsi, F; Collesi, C; Confalonieri, M; Crovella, S; Del Sal, G; Giacca, M; Guarnaccia, C; Kocijan, T; Long, C; Marcello, A; Martinelli, V; Myers, MP; Raspa, M; Rehman, M; Ring, N; Rossetti, G; Skoko, N; Vodret, S; Vukusic, K; Zacchigna, S | 1 |
| Chinnaboina, GK; Gupta, G; Liu, X; Mishra, A; Sharma, RK; Singh, M | 1 |
| Dawe, GS; Marwari, S | 1 |
| Fry, BR; Gifford, R; Johnson, AW; Manning, CE; Niwa, M; Robles, CF; Russell, N; Sawa, A | 1 |
| Bäckström, T; Bortolato, M; Cadeddu, R; Floris, G; Nordkild, P; Segerdahl, M | 1 |
| Jensen, R | 1 |
| Cavalcanti, DMLP; Cavalcanti, JRLP; da Silva, ANA; da Silva, MSM; de Araújo, DP; de Sales, LGP; Guzen, FP; Pinheiro, FI | 1 |
| Foute Nelong, T; Manduca, JD; Perreault, ML; Zonneveld, PM | 1 |
| Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R | 1 |
| Colantuoni, C; Furukori, K; Harada, K; Hiyama, H; Hookway, C; Huang, B; Jaaro-Peled, H; Kano, SI; Kondo, MA; Matsuoka, N; Ni, K; Pevsner, J; Pou, S; Sawa, A; Seshadri, S; Tajinda, K | 1 |
| Adamik, A; Telegdy, G | 1 |
| Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E | 1 |
| Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V | 1 |
| An, HM; Kosten, TR; Li, J; Shi, J; Tan, YL; Wang, YC; Wang, ZR; Yang, FD; Zhang, XY; Zhou, DF | 1 |
| Dovedova, EL; Khudoerkov, RM; Voronkov, DN | 1 |
| Ashraf-Khorassani, M; Castagnoli, N; Crowley, JJ; Sullivan, PF | 1 |
| Bleickardt, CJ; Hodgson, RA; Hunter, JC; Jones, NT; Kazdoba, TM | 1 |
| García, LI; Hernández, ME; Herrera-Meza, G; Manzo, J; Miquel, M | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Santos, R; Wuo-Silva, R | 1 |
| Konieczny, J; Lenda, T | 1 |
| Conway, MW; Francois, J; Gilmour, G; Huxter, J; Ishiwari, K; Li, J; Lowry, JP; Schwarz, AJ; Tricklebank, M | 1 |
| Abdu-Aguye, I; Hussaini, IM; Magaji, MG; Magaji, RA; Mohammed, M; Musa, AM | 1 |
| Cook, JM; Gill, KM; Grace, AA; Poe, MM | 1 |
| Alvarez-Cervera, FJ; Bata-García, JL; Erosa-Rivero, HB; Góngora-Alfaro, JL; Heredia-López, FJ | 1 |
| Ferger, B; Hengerer, B; Oeckl, P | 1 |
| Busanello, A; de Freitas, CM; de Moraes Reis, E; Fachinetto, R; Ferreira, J; Figueira, FH; Leal, CQ; Mello, CF; Röpke, J; Villarinho, JG | 1 |
| Blanchet, PJ; Lévesque, D; Mahmoudi, S | 1 |
| Ginovart, N; Tournier, BB | 1 |
| Dale, E; Doller, D; Gubellini, P; Kerkerian-Le Goff, L; Melon, C | 1 |
| Abílio, VC; Belangero, SI; Bressan, RA; Diana, MC; Gadelha, A; Han, SW; Melaragno, MI; Ota, VK; Santoro, ML; Santos, CM; Silva, PN; Stilhano, RS | 1 |
| Griesmaier, E; Hermann, M; Kiechl-Kohlendorfer, U; Obermair, GJ; Posod, A; Stanika, RI; Urbanek, M; Wechselberger, K; Wegleiter, K | 1 |
| Bagosi, Z; Jászberényi, M; Palotai, M; Tanaka, M; Telegdy, G | 1 |
| Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B | 1 |
| Ali, WB; Haleem, DJ; Khalil, S; Masroor, M; Pervez, S; Rais, Q; Shireen, E; Tariq, A | 1 |
| Fang, Y; Xu, L; Zhang, C | 1 |
| Li, A; Zhang, F | 1 |
| Ba-M'hamed, S; Bennis, M; Ouhaz, Z | 1 |
| Chaki, S; Hikichi, H; Kaku, A; Kambe, D; Karasawa, J; Kawaura, K; Kinoshita, K; Koike, H | 1 |
| Fujita, M; Hagino, Y; Hashimoto, M; Ikeda, K; Kasai, S; Kobayashi, K; Meltzer, HY; Setogawa, S; Yamaura, H; Yanagihara, D | 1 |
| Abdulbasit, A; Balogun, WG; Cobham, AE; Enye, LA; Ishola, AO; Nanakumo, ET; Obende, OM; Ogundele, OM | 1 |
| Aiello, R; Citraro, R; De Sarro, G; Leo, A; Pugliese, M; Russo, E | 1 |
| Melo-Thomas, L; Thomas, U | 1 |
| Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L | 1 |
| Hoekstra, M; Nahon, JE; Reuwer, AQ; van der Sluis, RJ; Van Eck, M | 1 |
| De Montis, MG; Ferrari, A; Gambarana, C; Pelliccia, T; Scheggi, S | 1 |
| Allenby, C; Hall, BJ; Kutlu, MG; Levin, ED; Slade, S | 1 |
| Foote, M; Graham, K; Qiao, H; Wu, Y; Zhou, Y | 1 |
| Borsini, F; Caprioli, A; Di Serio, S; Lombardo, K; Minetti, P; Pace, S; Riccioni, T; Stasi, MA; Vertechy, M | 1 |
| Ahuja, A; Al Rohaimi, AH; Ali, J; Baboota, S; Hassan, AA; Muslim, S; Mustafa, G | 1 |
| Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z | 1 |
| Abbiati, F; Bini, V; Bortolato, M; Caruso, D; Casti, A; Devoto, P; Frau, R | 1 |
| Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Hou, L; Qin, F; Wang, C; Wang, L; Wang, X; Wei, Y; Yu, Z; Zhou, W | 1 |
| Abilio, VC; Belangero, SI; Bressan, RA; Diana, MC; Moretti, PN; Ota, VK; Santoro, ML; Santos, CM; Spindola, LN; Xavier, G | 1 |
| Batisti, AP; Carlesso, MG; Donatello, N; dos Santos, AR; Emer, AA; Martins, DF; Mazzardo-Martins, L; Micke, GA; Piovezan, AP; Pizzolatti, MG; Venzke, D | 1 |
| An, HM; Kosten, TR; Li, J; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, YC; Wang, ZR; Yang, FD; Zhang, XY; Zhou, DF | 1 |
| Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J | 1 |
| Antonio, CB; Barreiro, EJ; Betti, AH; Fraga, CA; Herzfeldt, V; Rates, SM | 1 |
| Amalric, M; Degos, B; Deltheil, T; Kerkerian-Le Goff, L; Maurice, N; Melon, C; Mourre, C | 1 |
| Eder, M; Hladky, F; Holsboer, F; Schmidt, MV; Stepan, J; Uribe, A | 1 |
| Andrzejewski, K; Budzińska, K; Kaczyńska, K; Zaremba, M | 1 |
| Edelson, JR; Lewis, DA; Volk, DW | 1 |
| Hudson, MR; Jones, NC; O'Brien, TJ; Rind, G | 1 |
| Brake, WG; Ferris, CF; Kenkel, WM; Kulkarni, P; Madularu, D; Shams, WM; Yee, JR | 1 |
| Carey, RJ; Carrera, MP; Dias, FRC; Oliveira, LR; Santos, BG; Silva, JLL | 1 |
| An, HM; Li, J; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, YC; Wang, ZR; Wu, JQ; Yan, SX; Yang, FD; Zhang, XY | 1 |
| Cockeran, M; Dreyer, W; Harvey, BH; Sallinen, J; Shahid, M; Uys, M | 1 |
| Blobaum, AL; Bubser, M; Conn, PJ; Daniels, JS; Engers, DW; Hopkins, CR; Javitch, JA; Jones, CK; Lin, X; Lindsley, CW; Loch, MT; Niswender, CM; Rodriguez, AL; Thompson Gray, A | 1 |
| Bordia, T; Perez, XA; Quik, M; Zhang, D | 1 |
| Jensen, RJ | 1 |
| Jain, R; Meena, CL; Pant, AB; Rajput, SK; Sharma, AK; Sharma, SS | 1 |
| Burger, ME; da Silva Barcelos, RC; de David Antoniazzi, CT; Dias, VT; Kronbauer, M; Metz, VG; Roversi, K | 1 |
| An, HM; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, Z; Yang, F; Zhang, XY; Zhou, D | 1 |
| Echeverry-Alzate, V; Giné, E; Lopez-Moreno, JA; Perez-Castillo, A; Rodriguez de Fonseca, F; Santos, A | 1 |
| Funk, AJ; Koene, R; Lipska, BK; McCullumsmith, RE; Mielnik, CA; Newburn, E; Ramsey, AJ | 1 |
| Haleem, DJ; Samad, N; Yasmin, F | 1 |
| Imaki, J; Ishihara, S; Kawai, Y; Ohno, Y; Sasa, M; Shimizu, S; Sofue, N | 2 |
| Grzelak, ME; Hodgson, RA; Hunter, JC; Parker, EM; Pond, AJ; Varty, GB | 1 |
| Amato, D; Borsini, F; Nencini, P; Stasi, MA | 1 |
| Haleem, DJ; Haleem, MA; Samad, N | 1 |
| Amalric, M; Brotchie, JM; Johnston, TH; Lopez, S; Neuville, P; Schann, S; Turle-Lorenzo, N | 1 |
| Dhein, S; Mohr, FW; Perlitz, F | 1 |
| Barak, S; Weiner, I | 1 |
| Lin, Y; Quartermain, D; Stone, EA | 1 |
| Brown, AS; Butler, PD; Keegan, D; Palmer, AA; Rotrosen, J; Siska, LD; Susser, E | 1 |
| Feldon, J; Meyer, U; Schwarz, MJ; Spoerri, E; Yee, BK | 1 |
| Alam, MM; Anwer, T; Azam, F; Barodia, SK | 1 |
| Batool, F; Haleem, DJ | 1 |
| Chen, Y; Crespo, MI; Díaz, JL; Gross, RS; Jalali, K; Joswig, T; Kargo, W; Lanier, MC; Lechner, SM; Lin, E; Luo, Z; Malany, S; Markison, S; Moorjani, M; O'Brien, Z; Petroski, R; Piercey, J; Santos, M; Saunders, J; Slee, DH; Stotz, CE; Tellew, JE; Wen, J; Williams, JP; Zhang, X | 1 |
| Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI | 1 |
| Abel, T; Bizily, SF; Esposito, MF; Favilla, C; Kanes, SJ; Kelly, MP; Stein, JM; Vecsey, CG; Wand, G; Yang, X | 1 |
| Hu, G; Li, M; Sun, T | 1 |
| Barodia, SK; Luthra, PM; Raghubir, R | 1 |
| Arad, M; Weiner, I | 2 |
| Seeman, P | 1 |
| Baeyens, JM; Cendán, CM; Cobos, EJ; Del Pozo, E; Entrena, JM; Nieto, FR | 1 |
| Ahrens, AM; Ciucci, MR; Kane, JR; Ma, ST; Schallert, T; Windham, EB; Woodlee, MT | 1 |
| Ghose, S; Gleason, KA; Lewis-Amezcua, K; Potts, BW; Tamminga, CA | 1 |
| Acher, F; Amalric, M; Beurrier, C; Goudet, C; Gubellini, P; Kerkerian-LeGoff, L; Lhérondel, M; Lopez, S; Pin, JP; Révy, D; Selvam, C | 1 |
| Adams, C; Bilsky, EJ; Cormier, J; Dunbar, C; Mercer, H; Negus, SS; Stevenson, GW | 1 |
| Mahieu, M; Nordquist, RE; Pouzet, B; Schuurman, T; van der Staay, FJ | 1 |
| Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Emanuelli, T; Müller, LG; Pase, C; Reckziegel, P | 1 |
| Antle, MC; Brown, AR; Hu, B; Teskey, GC | 1 |
| Altunkaynak, BZ; Cetinkaya, R; Colak, S; Halici, Z; Keles, ON; Polat, B; Suleyman, H; Topal, A; Unal, B; Unal, D; Uyanik, A | 1 |
| Brand, L; Emsley, RA; Harvey, BH; Möller, M; Toua, C | 1 |
| Carter, EL; Koehler, RC; Martin, LJ; Torbey, MT; Yang, ZJ | 1 |
| Amalric, M; Flor, PJ; Greco, B; Lopez, S; van der Putten, H | 1 |
| Hanania, T; Paterson, NE | 1 |
| Mabrouk, OS; Marti, M; Morari, M | 1 |
| Lipina, T; Roder, J | 1 |
| Carayon, P; Couture, R; De Brito Gariepy, H; Ferrari, B | 1 |
| Calvo, EB; Khan, ZU; López-Aranda, MF; López-Téllez, JF; Masmudi-Martín, M; Montañez, EM; Navarro-Lobato, I | 1 |
| Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P | 1 |
| Cheng, WR; Jenkins, TA; Reynolds, GP; Zhang, XR; Zhang, ZJ | 1 |
| Becker, A; Grecksch, G; Keilhoff, G | 1 |
| De Carolis, L; Milella, MS; Nativio, P; Nencini, P; Passarelli, F; Scaccianoce, S; Schepisi, C | 1 |
| Biguzzi, S; Candeletti, S; Cavallo, M; Conti, C; Eleopra, R; Latini, F; Lettieri, C; Marti, M; Morari, M; Quatrale, R; Romualdi, P; Sarubbo, S; Sensi, M; Simonato, M; Zucchini, S | 1 |
| Gobaille, S; Krezel, W; Krzyzosiak, A; Muramatsu, S; Szyszka-Niagolov, M; Wietrzych, M | 1 |
| Borsini, F; De Carolis, L; Nencini, P; Serlupi-Crescenzi, O; Stasi, MA | 1 |
| Creed, M; Hamani, C; Nobrega, JN | 1 |
| Aguilar-Alonso, P; Baltazar-Gaytán, E; Bringas, ME; Flores, G; León-Chávez, BA; Negrete-Díaz, JV; Newton, S; Vazquez-Roque, RA | 1 |
| Bubenikova-Valesova, V; Horacek, J; Sumiyoshi, T; Svoboda, J | 1 |
| Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M | 1 |
| Federley, M; Fjällström, AK; Persson, P; Stenqvist, P; Wadenberg, ML | 1 |
| Dias, R; Goetghebeur, PJ; Lerdrup, L; Sylvest, A | 1 |
| Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y | 1 |
| Chen, L; Xue, Y | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| Bishnoi, M; Chopra, K; Kulkarni, SK; Rongzhu, L | 1 |
| Laplante, F; Lappi, DA; Sullivan, RM | 1 |
| Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Ourique, AF; Pase, CS; Reckziegel, P | 1 |
| Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F | 1 |
| Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP | 1 |
| De Carolis, L; Milella, MS; Nencini, P; Schepisi, C | 1 |
| Evinger, C; Horn, KG; Hui, C; Kaminer, J; Powers, AS | 1 |
| Broner, EC; Greenbaum, L; Kohn, Y; Lerer, B; Lifschytz, T; Slonimsky, A; Zozulinsky, P | 1 |
| Bonan, CD; Piato, AL; Savio, LE; Vuaden, FC; Wyse, AT | 1 |
| Dobryakova, YV; Dubynin, VA; Luijtelaar, GV | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Hiray, Y; Langade, P; Patil, R; Shinde, S | 1 |
| Bishnoi, M; Boparai, RK | 1 |
| Bilge, U; Erol, K | 1 |
| Banasikowski, TJ; Beninger, RJ | 1 |
| Bauer, M; Blaich, C; Falkai, P; Gruber, O; Rietschel, M; Schmitt, A; Schneider-Axmann, T; Schulze, T; Treutlein, J; Wilmsdorff, MV; Zink, M | 1 |
| Le Pelley, M; Schmidt-Hansen, M | 1 |
| Afzal, M; Ahmed, S; Ahmed, Z; Anwar, F; Ashraf, MS; Gupta, G; Kazmi, I; Khusroo, MJ; Mujeeb, M; Nazeer, K; Rahman, M; Saleem, S | 1 |
| Bacolod, MD; Bennouar, KE; Cajina, M; Doller, D; Gubellini, P; Jimenez, HN; Kerkerian-Le Goff, L; Melon, C; Uberti, MA | 1 |
| Benninghoff, J; Braun, I; Genius, J; Giegling, I; Hartmann, A; Möller, HJ; Reuter, N; Rujescu, D | 1 |
| Antonello Rubin, M; da Cunha, C; da Silva Sant'Anna, G; de Almeida Cabrini, D; de Vargas Pinheiro, F; Dombrowski, PA; Fachinetto, R; Ferreira, J; Gauze Bonacorso, H; Machado, P; Pinto Martins, MA; Villarinho, JG; Zanatta, N | 1 |
| Ionov, ID; Severtsev, NN | 1 |
| Ansari, MS; Baldwin, RM; Bubser, M; Conn, PJ; Johnson, KA; Jones, CK; Marvanova, M; Niswender, CM; Tantawy, MN | 1 |
| Akhtar, M; Goswami, D; Joshi, M; Khuroo, AH; Najmi, AK | 1 |
| Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA | 1 |
| Basar, K; Ertugrul, A; Ozdemir, H; Saka, E | 1 |
| Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG | 1 |
| Ellis, LD; Soanes, KH | 1 |
| Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY | 1 |
| Gurling, HM; Harrison, A; Hunt, SP; McQuillin, A; Ng, A; Rizig, MA; Robinson, M; Zvelebil, M | 1 |
| Bridgman, A; Creed, MC; Fletcher, PJ; Hamani, C; Nobrega, JN | 1 |
| Feng, YB; McAlonan, GM; Sze, SC; Wang, D; Wang, XM; Wong, HK; Zhang, L; Zhang, ZJ | 1 |
| Andreeva, TV; Dygai, AM; Ermolaeva, LA; Khmelevskaya, ES; Krupin, VA; Pershina, OV; Reztsova, AM; Skurikhin, EG; Stepanova, IE | 1 |
| Gershteĭn, LM; Rakhmanova, VI; Sergutina, AV; Tatarintseva, IM | 1 |
| Avakyan, GN; Goldstein, N; Goldstein, R; Kamensky, AA; Kovalev, GI; Terterov, D; Terterov, S; Zolotarev, YA | 1 |
| González-Maeso, J; Holloway, T; Moreno, JL; Rayannavar, V; Sealfon, SC; Umali, A | 1 |
| Kirchhoff, BA; Smith, SE; Taylor, GT | 1 |
| Li, M; Sparkman, NL | 1 |
| Ikarashi, Y; Kanno, H; Kase, Y; Sekiguchi, K; Yamaguchi, T | 1 |
| Panagis, G; Rea, E; Schmidt, TT; Shababi-Klein, J; Winter, C | 1 |
| Du, RH; Fan, Y; Hu, G; Su, CJ; Xu, XQ | 1 |
| Cheng, JT; Li, JS | 1 |
| Achaval, M; Baptista, PP; Blank, M; de Senna, PN; do Nascimento, P; Ilha, J; Mestriner, RG; Paim, MF; Saur, L; Vianna, MR; Xavier, LL | 1 |
| Coffman, CF; Fiacco, NR; Granger, JC; Helton, BM; Jackson, JC; Kim, LV; Kreiss, DS; Mistry, RS; Mizer, TM; Palmer, LV; Vacca, JA; Winkler, SS; Zimmer, BA | 1 |
| Asinof, SK; Diehl, GW; Frackman, A; Leffler, J; Paine, TA | 1 |
| Drummond, JB; Haroutunian, V; Lucas, EK; McCullumsmith, RE; Meador-Woodruff, JH; Shan, D | 1 |
| Goto, Y; O'Donnell, P | 1 |
| Adler, LE; Freedman, R; Simosky, JK; Stevens, KE | 1 |
| Bhattachary, SK; Bhattacharya, D; Muruganandam, AV | 1 |
| Klein, A; Schmidt, WJ | 1 |
| Gaisler-Salomon, I; Weiner, I | 1 |
| Chang, M; Gabriele, J; Henry, P; Johnson, RL; Mishra, RK; Paladino, P; Saeedi, H; Sharma, S | 1 |
| Abílio, VC; Barbosa, PN; Carvalho, RC; Frussa-Filho, R; Silva, RH | 1 |
| Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL | 1 |
| Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S | 1 |
| Gmiro, VE; Gorbunova, LV; Lukomskaya, NY; Rukoyatkina, NI | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Sugiyama, A | 1 |
| Gerum, SV; Javitt, DC; Linn, GS; Negi, SS | 1 |
| Mitsunaga, H; Ukai, M | 1 |
| Nachman, R; Rehavi, M; Weiner, I; Zuckerman, L | 1 |
| Harvey, BH; Nel, A | 1 |
| Kulkarni, SK; Naidu, PS; Singh, A | 2 |
| Aamo, TO; Andreassen, OA; Beal, MF; Ferrante, RJ; Jørgensen, HA | 1 |
| Ossowska, K; Pietraszek, M; Wardas, J; Wolfarth, S | 1 |
| Meredith, GE; Napier, TC; Switzer, RC | 1 |
| Costentin, J; El Yacoubi, M; Vaugeois, JM | 1 |
| Betz, A; Correa, M; Dobson, DR; O'Neill, MF; O'Neill, MJ; Salamone, JD; Wisniecki, A | 1 |
| Braus, DF; Henn, FA; May, B; Müller, B; Schmitt, A; Zink, M | 1 |
| Baba, A; Hashimoto, H; Shintani, N; Tanaka, K | 1 |
| Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S | 1 |
| Feifel, D; Melendez, G; Shilling, PD | 1 |
| Hamann, M; Meisler, MH; Richter, A | 1 |
| Heresco-Levy, U; Javitt, DC; Mazeh, H; Shoham, S | 1 |
| Ando, N; Morimoto, K; Ninomiya, T; Suwaki, H; Watanabe, T | 1 |
| Flumerfelt, BA; Hussain, N; Rajakumar, N | 1 |
| Braus, DF; Demirakca, T; Henn, FA; May, B; Müller, B; Schmitt, A; Zink, M | 1 |
| Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M | 1 |
| Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F | 1 |
| Dall'Igna, OP; de Oliveira, RV; Fett, P; Gomes, MW; Lara, DR; Mantese, CE; Schuh, J; Souza, DO; Tort, AB | 1 |
| Ethier, I; Kagechika, H; Lévesque, D; Rouillard, C; Shudo, K | 1 |
| Fairfax, DF; Gupta, SK; Henry, P; Khan, RF; Mishra, RK; N-Marandi, S; Rogoza, RM | 1 |
| Kohles, T; Kovar, KA; Lebsanft, HB; Schmidt, WJ | 1 |
| Laszczyńska, M; Piasecka, M; Słuczanowska-Glabowska, S; Wylot, M | 1 |
| Alves, A; Burger, ME; Callegari, L; Fachineto, R; Rocha, JB | 1 |
| Kapur, S; Nobrega, JN; Remington, G; Turrone, P | 1 |
| Arima, K; Barr, AM; Dwork, AJ; Falkai, P; Honer, WG; Nakamura, M; Phillips, AG; Sawada, K; Young, CE | 1 |
| Fletcher, PJ; Kapur, S; Tenn, CC | 1 |
| Del Bel, EA; Lazzarini, M; Salum, C | 1 |
| Barnouin, MC; Chabot, C; Depoortere, R; Griebel, G; Perrault, G; Scatton, B; Terranova, JP | 1 |
| Ding, JH; Hu, G; Hu, LF; Wang, S; Yang, Y | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Schiller, D; Weiner, I; Zuckerman, L | 1 |
| Boffa, E; Kennedy, JL; Likhodi, O; Lipska, BK; Van Tol, HH; Weinberger, DR; Wong, AH | 1 |
| Gur, RE; Kanes, SJ; Lerman, C; Liang, Y; Majumdar, S; Maxwell, CR; Siegel, SJ; Trief, DF | 1 |
| Konieczny, J; Ossowska, K; Pilc, A; Wolfarth, S | 1 |
| Hyland, BI; Parr-Brownlie, LC | 1 |
| Henderson, JM; Johnston, GA; Schleimer, SB | 1 |
| Abe, J; Hamada, Y; Harada, T; Hashimoto, K; Horii, I; Sawada, Y; Shiotani, M | 1 |
| Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R | 1 |
| Bartoszyk, GD; Lin, Y; Quartermain, D; Rosengarten, H | 1 |
| Benke, D; Bluethmann, H; Dong, Y; Feldon, J; Fritschy, JM; Hagenbuch, N; Keist, R; Malenka, RC; Möhler, H; Rudolph, U; Studer, R; von Boehmer, L; Yee, BK | 1 |
| Bonikovski, V; Futuro-Neto, HA; Pires, JG | 1 |
| Barsvári, B; Haller, J; Levay, G; Leveleki, C; Mikics, E; Soproni, K; Sziray, N | 1 |
| Mahadik, SP; Parikh, V; Pillai, A; Terry, AV | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Pietraszek, M; Schaefer, D | 1 |
| Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E | 1 |
| Burne, TH; Eyles, DW; Kesby, JP; McGrath, JJ | 1 |
| Becker, S; Kapur, S; Li, M; Smith, AJ | 1 |
| Bilsky, EJ; Negus, SS; Stevenson, GW | 1 |
| Abel, T; Kanes, SJ; Kelly, MP; Liang, Y; Maxwell, CR; Siegel, SJ | 1 |
| Burger, ME; Fachinetto, R; Pereira, RP; Perottoni, J; Rocha, JB; Wagner, C; Zeni, G | 1 |
| de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D | 1 |
| Decker, S; El-Mallakh, RS; El-Masri, MA; Huff, MO; Levy, RS; Li, XP; Morris, M | 1 |
| Baik, JH; Choi, JH; Han, PL; Kim, HS; Kim, JI; Kim, YS; Kwon, J; Lee, KW; Lee, SJ; Lee, T; Ryu, SH; Shin, SW; Song, M; Suh, PG; Yumkham, S | 1 |
| Bishnoi, M; Chopra, K; Kulkarni, SK | 4 |
| Blennow, K; Davidsson, P; Ljung, E; Martin, P; Paulson, L | 1 |
| Hulick, VC; Turgeon, SM | 1 |
| Blank, M; Brodsky, O; Chapman, J; Katzav, A; Pick, CG; Reichlin, M; Shoenfeld, Y; Solodeev, I; Zhang, W | 1 |
| Betancur, C; Billard, JM; Denis, C; Epelbaum, J; Giros, B; Mathieu, F; Morice, E; Nosten-Bertrand, M | 1 |
| Hashioka, S; Kanba, S; Kato, T; Monji, A | 1 |
| Arnt, J; Didriksen, M; Skarsfeldt, T | 1 |
| Constantino, L; Dal-Pizzol, F; de Albuquerque, IM; Machado, RA; Martins, MR; Menna-Barreto, S; Quevedo, J; Streck, E | 1 |
| Amitai, N; Markou, A; Semenova, S | 1 |
| Haleem, DJ; Ikram, H; Samad, N | 1 |
| Feifel, D; Melendez, G; Priebe, K; Shilling, PD | 1 |
| Bender, A; Braun, I; Genius, J; Grunze, H; Möller, HJ; Rujescu, D | 1 |
| Bortolato, M; Castelli, MP; Fà, M; Frau, R; Gessa, GL; Marrosu, F; Mereu, G; Orrù, M; Piras, AP; Puligheddu, M; Tuveri, A | 1 |
| Andersen, JS; Marcello, S; Mongeau, R; Pani, L | 1 |
| Kim, D; Koh, HY; Lee, J; Lee, S; Shin, HS | 1 |
| Schlenker, EH | 1 |
| Betuing, S; Brouillet, E; Caboche, J; Charvin, D; Déglon, N; Deyts, C; Luthi-Carter, R; Pagès, C; Perrin, V; Régulier, E; Roze, E | 1 |
| de Lima, TC; Duarte, FS; Lach, G; Martins, PR; Romeiro, GA | 1 |
| Dai, XM; Lu, Y; Ma, HW; Yao, Y | 1 |
| Neill, JC; Snigdha, S | 1 |
| Dean, B; McLeod, MC; Sundram, S | 1 |
| Martinez, V; Sarter, M | 1 |
| Dawe, GS; Grigoryan, GA; Gross, KW; Jones, CA; Ong, WY; Ratty, AK; Salvi, R; Stolzberg, D; Tan, CH; Verma, V | 1 |
| Abdul Haleem, M; Haider, S; Haleem, DJ; Khan, A; Perveen, T; Samad, N | 1 |
| Abumaria, N; Flügge, G; Fuchs, E; Havemann-Reinecke, U; Hiemke, C; Rüther, E; Rygula, R; Zernig, G | 1 |
| Jenner, P; Marsden, CD; Reavill, C | 1 |
| Glassman, HN; Glassman, RB | 1 |
| Jalfre, M; Porsolt, RD | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 2 |
| Lapierre, YD; Rastogi, RB; Rastogi, SK; Singhal, RL | 2 |
| Andreas, K; Fischer, HD; Schmidt, J | 1 |
| Stricker, EM; Zigmond, MJ | 1 |
| Curtin, J; Fields, J; Koller, W | 1 |
| Herrera-Marschitz, M; Olson, L; Olsson, D; Strömberg, I; Ungerstedt, U | 1 |
| Baker, HJ; Cox, N; Lorden, JF; McKeon, TW; Walkley, SU | 1 |
| Allikmets, LKh; Avrutskiĭ, GIa; Beliakov, AV; Neduva, AA; Zharkovskiĭ, AM | 1 |
| Catron, AC; Farber, JP; Krous, HF | 1 |
| Kanaya, T; Sarai, K; Sera, H; Yonekawa, M | 1 |
| Alanen, E; Pohto, P; Sundén-Kuronen, B | 1 |
| Fink, H; Morgenstern, R; Oelssner, W | 1 |
| Bowden, DM; Dubach, MF | 1 |
| Concannon, JT; Schechter, MD | 1 |
| Antolik, EK; Faison, EP; Yarbrough, GG | 1 |
| Bédard, PJ; Boucher, R; Larochelle, L | 1 |
| Cheng, JT; De Ryck, M; Schallert, T; Teitelbaum, P | 1 |
| Borison, R; Diamond, BI; Reyes, MG | 1 |
| Canonico, PL; Clementi, G; Fiore, L; Gessa, GL; Nicoletti, F; Patti, F; Scapagnini, U; Tigano, G | 1 |
| Johnels, B; Steg, G | 1 |
| Diamond, BI; Gordon, JH | 1 |
| Katz, RJ; Sibel, M | 1 |
| Davidson, AB | 1 |
| Andreassen, OA; Jørgensen, HA | 1 |
| Matsumoto, RR; Stone, MR; Truong, DD; van't Groenewout, JL; Vo, VN | 1 |
| Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ | 1 |
| Feldon, J; Rawlins, JN; Yee, BK | 1 |
| Diana, M; Gessa, GL; Lilliu, V; Mereu, G; Muntoni, AL; Vargiu, P | 1 |
| Culić, M; Janković, B; Rakić, L; Saponjić, J | 1 |
| Aliev, AN; Aliev, MN; Mamedbeĭli, TN; Rzaev, RN | 1 |
| Friedman, MB; Gao, XM; Kakigi, T; Tamminga, CA | 1 |
| Andreassen, OA; Hole, K; Jørgensen, HA | 1 |
| Hasegawa, T; Kameyama, T; Katsumata, Y; Kinoshita, H; Nabeshima, T; Yamamoto, I | 1 |
| LeDuc, PA; Mittleman, G | 1 |
| Corbett, R; Cornfeldt, M; Dunn, RW; Smith, C; Szewczak, M; Woods, A | 1 |
| Nezlin, L; Sakharov, D; Voronezhskaya, E | 1 |
| Gao, XM; Kakigi, T; Moran, M; Tamminga, CA; Thaker, GK | 1 |
| Cao, H; Xu, JH; Zheng, JH | 1 |
| Ijaz, S; Shuaib, A; Wishart, TB | 1 |
| Gerlach, J; Peacock, L | 1 |
| Albergati, A; Bo, P; Murelli, R; Savoldi, F; Soragna, D | 1 |
| Löscher, W; Richter, A | 1 |
| Arushanian, EB; Ovanesov, KB; Popov, AV; Popova, AP; Shchetinin, EV | 1 |
| Glenthøj, B; Hemmingsen, R; Holm, S; Laursen, H; Mogensen, J | 1 |
| Rudolf, G; Wioland, N | 1 |
| Jaskiw, GE; Lipska, BK; Weinberger, DR | 1 |
| Geyer, MA; Swerdlow, NR | 1 |
| Albergati, A; Bo, P; Candeloro, E; Marchioni, E; Savoldi, F; Soragna, D | 1 |
| Lorenc-Koci, E; Ossowska, K; Wolfarth, S | 1 |
| Hashimoto, K; Kirsch, JR; Koehler, RC; London, ED; Takahashi, H; Traystman, RJ | 1 |
| Hosono, T; Ikura, Y; Kudo, T; Niigawa, H; Nishimura, T; Sakamoto, S; Takeda, M; Taniguchi, N; Tanii, H | 1 |
| Maurice, T; Privat, A | 1 |
| Lipska, BK; Weinberger, DR | 1 |
| George, B; Kulkarni, SK | 1 |
| Kostowski, W; Krzaścik, P | 1 |
| Adams, CE; Johnson, RG; Nagamoto, H; Rose, GM; Stevens, KE | 1 |
| Sams-Dodd, F | 1 |
| Jentsch, JD; Roth, RH; Taylor, JR | 1 |
| Gao, XM; Hashimoto, T; Medoff, DR; Ross, DE; Tamminga, CA | 1 |
| Fowler, SC; Wang, G | 1 |
| Areso, MP; García-Vallejo, P; Giralt, MT; Gómez, FM; Sainz, B | 1 |
| Ishigooka, J; Kobayashi, K; Miura, S; Takeuchi, H; Watanabe, S | 1 |
| Campbell, IG; Feinberg, I | 1 |
| Konieczny, J; Lorenc-Koci, E; Ossowska, K; Wolfarth, S | 1 |
| Andreassen, OA; Finsen, B; Jørgensen, HA; Ostergaard, K; Sørensen, JC; West, MJ | 1 |
| Kleven, MS; Koek, W; Prinssen, EP | 1 |
| Japha, K; Koch, M | 1 |
| Caron, MG; Gainetdinov, RR; Koller, BH; Mohn, AR | 1 |
| Chinen, CC; Frussa-Filho, R | 1 |
| Feldon, J; Jongen-Rêlo, AL; Pouzet, B; Weiner, I; Zhang, W | 1 |
| Chatterjee, SS; Nöldner, M | 1 |
| Adachi, K; Cools, AR; Hasegawa, M; Hirose, N; Ikeda, H; Koshikawa, N; Sato, M | 1 |
| Casey, DE | 1 |
| Field, EF; Pellis, SM; Whishaw, IQ | 1 |
| Kapur, S; Remington, G; Wadenberg, ML | 1 |
| Fendt, M; Koch, M; Schwienbacher, I | 1 |
| Andreatini, R; Beijamini, V; Joca, SR; Skalisz, LL; Vital, MA | 1 |
| Horikomi, K; Miwa, T; Takahashi, S | 1 |
| De Souza, IE; Egan, MF; Hyde, TM; Meredith, GE; Tipper, G; Wong, ML | 1 |
| Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP | 1 |
| Binder, EB; Kilts, CD; Kinkead, B; Nemeroff, CB; Owens, MJ | 1 |
| Higuchi, H; Sato, K; Shimizu, T; Takahashi, H; Yoshida, K | 1 |
| Anic, T; Aralica, G; Bilic, I; Buljat, G; Ivankovic, D; Mikus, D; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rotkvic, I; Rucman, R; Seiwerth, S; Separovic, J; Sikiric, P; Stancic-Rokotov, D; Zoricic, I | 1 |
| Dai, J; Guan, HJ; Zhu, XZ | 1 |
| Dygai, AM; Gol'dberg, ED; Provalova, NV; Skurikhin, EG; Suslov, NI; Zyuz'kov, GN | 1 |
| Crocker, AD; Hemsley, KM | 1 |
| Kanazir, S; Rakic, L; Ruzdijic, S; Veskov, R; Vukosavic, S | 1 |
| Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S | 1 |
| Bruhwyler, J; Cools, AR; Ellenbroek, BA; Liégeois, JF | 1 |
| Kurasawa, M; Nakamura, K | 1 |
| Ross, BM; Seeman, M; Turenne, SD | 1 |
| Coenen, AM; Kuznetsova, GD; Midzianovskaia, IS; Spiridonov, AM; van Luijtelaar, EL | 1 |
| Chang, CK; Chien, CH; Chou, HL; Lin, MT | 1 |
| Bertorelli, R; Costentin, J; El Yacoubi, M; Ledent, C; Ongini, E; Parmentier, M; Vaugeois, JM | 1 |
| Costain, WJ; Crocker, SF; Denovan-Wright, EM; Hamilton, LC; MacGibbon, GA; Murphy, KM; Robertson, HA | 1 |
| Bhattacharya, D; Bhattacharya, SK; Ghosal, S; Sairam, K | 1 |
| Le Pen, G; Moreau, JL | 1 |
| Andersson, C; Hamer, RM; Lawler, CP; Lieberman, JA; Mailman, RB | 1 |
| Kozlovskaia, MM; Val'dman, AV | 1 |
| Dill, RE; Dorris, RL; Phillips-Thonnard, I | 1 |
| Crossman, AR; Sambrook, MA; Slater, P | 1 |
| Gillin, JC; Moja, EA; Stoff, DM; Wyatt, RJ | 1 |
| Anlezark, GM; Marsden, CD; Meldrum, BS | 1 |
| Santelli, S; Weiss, B | 1 |
| Klawans, HL; Koller, WC; Nausieda, PA; Weiner, WJ | 1 |
| Borison, RL; Diamond, BI; Havdala, HS | 1 |
| Davis, KL; Hollister, LE; Simonton, S; Vento, AL | 1 |
| Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Aliev, MN; Kryzhanovskiĭ, GN | 1 |
| Hitri, A; Klawans, HL | 1 |
| Battista, AF; Goldstein, M; Matsumoto, Y; Miyamoto, T | 1 |
| Bárány, S; Gunne, LM | 1 |
| Asper, H; Bürki, HR; Ruch, W; Sayers, AC | 1 |
| Collu, M; Diana, M; Gessa, GL; Mura, A | 1 |
| Chen, YJ; Chiou, GC | 1 |
| Décio, RC; Frussa-Filho, R; Monteiro, Mdo C; Soares, CG | 1 |
| Boyet, S; Marescaux, C; Nehlig, A; Vergnes, M | 1 |
| Bachus, SE; Dale, J; Goodman, L; Kaneda, H; Shirakawa, O; Tamminga, CA | 1 |
| Auchus, AP; Pickel, VM | 1 |
| Fujita, Y; Ishihara, K; Kishimoto, T; Sasa, M; Serikawa, T; Takaori, S; Ujihara, H; Xie, RM; Yamada, J; Yoshimura, M | 1 |
| Casey, DE; Gerlach, J | 1 |
| Iversen, SD; Rupniak, NM; Tye, SJ | 1 |
| Messiha, FS | 1 |
| Dale, JM; Goodman, L; Kaneda, H; Kaneda, N; Tamminga, CA | 1 |
| Feldon, J; Weiner, I | 1 |
| Miyamoto, K | 1 |
| Johnson, CJ; McCullough, LD; Salamone, JD; Steinpreis, RE | 1 |
| Keck, PE; McElroy, SL; Pope, HG; Seeler, DC | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, SJ | 1 |
| Casas, M; Ferré, S; Guix, T; Jane, F; Prat, G | 1 |
| Fowler, SC; Liao, RM; Skjoldager, P | 1 |
| Ellison, G; See, RE | 1 |
| Aravagiri, M; Ellison, GD; See, RE | 1 |
| Aldes, LD; Brigham, TE; Chronister, RB; Marco, LA; Pendleton, R; Reed, TF | 1 |
| Vamvakides, A | 1 |
| Carvey, P; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Gunne, LM; Häggström, JE | 1 |
| Domino, EF | 1 |
| Jenner, P; Marsden, CD; Rupniak, NM | 1 |
| Hagenmeyer-Houser, SH; Russell, KH; Sanberg, PR | 1 |
| Hashizume, K; Manaka, S; Sasaki, M; Takakura, K | 1 |
| Chahl, LA; Corlis, A; Kavanagh, CA | 1 |
| Barros, HM; Leite, JR | 1 |
| Carvey, P; Goetz, CG; Klawans, HL; Paulseth, JE | 1 |
| Schmajuk, NA | 1 |
| Chen, YC; Chesire, RM; Pellis, SM; Teitelbaum, P | 1 |
| Bédard, P; Boucher, R; Langelier, P; Larochelle, L; Parent, A; Poirier, LJ; Roberge, AG | 1 |
| Poirier, LJ | 1 |
| Blom, S; Thulin, CA | 1 |
| Hedeman, LS; Sil, R | 1 |
| Chen, G; Chen, X; Cheng, Y; Cui, Y; Cui, Z; Li, P; Li, Q; Liu, Z; Yao, L; Zhang, F; Zhang, K; Zhang, N; Zhang, S | 1 |
| Adeodato, CS; Alves, GG; Barbosa, IB; Campos, CA; de Araújo, VC; de Noronha, F; Montalli, V; Napimoga, M; Scelza, MZ; Scelza, P | 1 |
| Jiang, J; Li, DZ; Miao, Y | 1 |
| David, C; Elliott, H; Farnfield, B; Golder, J; Hadingham, SJ; Hunter, AJ; Parsons, AA; Roberts, JC; Virley, D; Whelan, G | 1 |
| Chen, H; Levin, L; Ritter, AL; Teixeira, FB; Trope, M | 1 |
| Chang, Y; Chiu, YT; Hwang, B; Lu, JH; Sung, HW; Yang, PC | 1 |
| Fregert, S; Thorgeirsson, A | 1 |
| Gao, Z; Huan, Q; Peng, J; Wu, P; Xiao, H; Zhang, Y | 1 |
9 review(s) available for haloperidol and Disease Models, Animal
| Article | Year |
|---|---|
Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.
Topics: Animals; Catalepsy; Disease Models, Animal; Haloperidol; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Haloperidol; Humans; Inhibition, Psychological; Schizophrenia; Schizophrenic Psychology | 2012 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cation Transport Proteins; Cisapride; Disease Models, Animal; Dogs; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Gastrointestinal Agents; Haloperidol; Histamine H1 Antagonists; Long QT Syndrome; Potassium Channels; Potassium Channels, Voltage-Gated; Sulpiride; Terfenadine; Torsades de Pointes | 2003 |
[Effect of antipsychotics on glutaminergic neural transmission in the animal model].
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Disease Models, Animal; Haloperidol; Humans; Long-Term Care; Neuronal Plasticity; Neurons; Rats; Receptors, Glutamate; Schizophrenia; Synaptic Transmission | 2004 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Humans; Mastication; Neurotoxicity Syndromes; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine | 2000 |
Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2000 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal; Drug Synergism; Dystonia; Fluphenazine; Haloperidol; Histamine H1 Antagonists; Levodopa; Mastication; Methyltyrosines; Movement Disorders; Parasympatholytics; Physostigmine; Primates; Rats | 1986 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dopamine; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Olivary Nucleus; Parkinson Disease; Putamen; Rats; Red Nucleus; Substantia Nigra; Thalamic Nuclei; Tremor | 1974 |
1 trial(s) available for haloperidol and Disease Models, Animal
| Article | Year |
|---|---|
Clozapine in tardive dyskinesia: observations from human and animal model studies.
Topics: Adult; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Haloperidol; Humans; Male; Rats; Schizophrenia; Treatment Outcome | 1994 |
506 other study(ies) available for haloperidol and Disease Models, Animal
| Article | Year |
|---|---|
Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists.
Topics: Animals; Bromocriptine; Cycloheptanes; Disease Models, Animal; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Structure-Activity Relationship; Tropolone | 1984 |
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Mice; Piperidines; Protein Binding; Psychomotor Agitation; Psychotic Disorders; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2001 |
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug Evaluation, Preclinical; Erectile Dysfunction; Ferrets; Humans; Male; Models, Molecular; Molecular Structure; Oximes; Piperazines; Rats; Rats, Wistar; Receptors, Dopamine D4; Stereoisomerism; Structure-Activity Relationship | 2006 |
Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
Topics: Acetamides; Animals; Antipsychotic Agents; Combinatorial Chemistry Techniques; Disease Models, Animal; Head Movements; Mice; Molecular Structure; Motor Activity; Piperazines; Quipazine; Serotonin 5-HT2 Receptor Antagonists | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.
Topics: Animals; Carbazoles; Disease Models, Animal; Dopamine Agonists; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists | 2009 |
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Agonists; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship | 2010 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Stability; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Parkinson Disease; Pyridones; Recombinant Proteins; Structure-Activity Relationship | 2012 |
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Disease Models, Animal; Models, Molecular; Molecular Structure; Piperazine; Piperazines; Purines; Pyrimidinones; Structure-Activity Relationship | 2015 |
Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.
Topics: Analgesics, Non-Narcotic; Animals; Chemistry Techniques, Synthetic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Formaldehyde; Guinea Pigs; Ligands; Mice; Neuralgia; Pain Measurement; Pyridazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Rotarod Performance Test; Structure-Activity Relationship | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Receptors, Serotonin; Structure-Activity Relationship | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dopamine Agonists; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Mice; Mice, Inbred ICR; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 2021 |
Therapeutic potential of TAK-071, a muscarinic M
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; CHO Cells; Cognition; Cognitive Dysfunction; Cricetulus; Disease Models, Animal; Haloperidol; Humans; Memory, Short-Term; Mice; Mice, Transgenic; MicroRNAs; Muscarinic Agonists; Olanzapine; Quetiapine Fumarate; Receptor, Muscarinic M1; Recombinant Proteins; Schizophrenia; Social Behavior | 2021 |
Haloperidol and methylphenidate alter motor behavior and responses to conditioned fear of Carioca Low-conditioned Freezing rats.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Fear; Freezing Reaction, Cataleptic; Haloperidol; Hyperkinesis; Male; Methylphenidate; Motor Activity; Rats; Rats, Wistar | 2021 |
Antidepressant, anti-amnesic and vasoprotective effect of Bombax costatum Pellegr. & Vuillet aqueous stem bark extract on chronic mild unpredictable stress induced in rat.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Bombax; Depression; Depressive Disorder, Major; Disease Models, Animal; Haloperidol; Hippocampus; Plant Bark; Rats; Serotonin; Stress, Psychological; Sucrose | 2022 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Disease; Rats | 2023 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL; Monoterpenes; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2022 |
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.
Topics: Aged; Aged, 80 and over; Aging; Animals; Antipsychotic Agents; Autopsy; Datasets as Topic; Disease Models, Animal; Female; Functional Laterality; Haloperidol; Humans; Immunohistochemistry; Intermediate Filaments; Male; Middle Aged; Motor Cortex; Olanzapine; Parvalbumins; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Regression Analysis; Schizophrenia | 2023 |
Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Epigenesis, Genetic; Glial Cell Line-Derived Neurotrophic Factor; Haloperidol; Humans; Ketamine; Nerve Growth Factor; Rats; Schizophrenia | 2023 |
Pharmacological and proteomic analyses of neonatal polyI:C-treated adult mice.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Animals, Newborn; Antipsychotic Agents; Clozapine; Disease Models, Animal; Exploratory Behavior; Female; Haloperidol; Hippocampus; Hydrolases; Interpersonal Relations; Mice; Microtubule-Associated Proteins; Nerve Tissue Proteins; Poly I-C; Pregnancy; Prepulse Inhibition; Proteomics; Recognition, Psychology; Schizophrenia; Sensory Gating | 2019 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
Haloperidol-induced hypokinesia in rats is differentially affected by the light/dark phase, age, and melatonin.
Topics: Age Factors; Animals; Behavior, Animal; Central Nervous System Depressants; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol; Hypokinesia; Melatonin; Photoperiod; Rats; Rats, Sprague-Dawley | 2020 |
Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson's disease.
Topics: Albizzia; Animals; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Haloperidol; Motor Skills; Parkinson Disease, Secondary; Plant Extracts; Rats; Rats, Wistar | 2019 |
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosan; Disease Models, Animal; Dopamine Agonists; Drug Carriers; Female; Haloperidol; Humans; Male; Nanoparticles; Neurons; Oxidopamine; Parkinson Disease, Secondary; Particle Size; Rats; Tetrahydronaphthalenes; Thiophenes; Toxicity Tests, Acute | 2020 |
Preference for vigorous exercise versus sedentary sucrose drinking: an animal model of anergia induced by dopamine receptor antagonism.
Topics: Animals; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Male; Maze Learning; Mice; Motivation; Motor Activity; Physical Conditioning, Animal; Sucrose | 2020 |
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment.
Topics: Animals; Antipsychotic Agents; Brain; Cannabidiol; Cerebrovascular Circulation; Disease Models, Animal; Female; Gene Expression Regulation; Haloperidol; Magnetic Resonance Imaging; Male; Methylazoxymethanol Acetate; Models, Molecular; Molecular Dynamics Simulation; Pregnancy; Prenatal Exposure Delayed Effects; Puberty; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia | 2020 |
Playback of 50-kHz ultrasonic vocalizations overcomes psychomotor deficits induced by sub-chronic haloperidol treatment in rats.
Topics: Acoustic Stimulation; Animals; Disease Models, Animal; Dopamine Antagonists; Exploratory Behavior; Haloperidol; Male; Psychomotor Disorders; Rats; Rats, Wistar; Ultrasonic Therapy; Vocalization, Animal | 2020 |
Regulatory effects of Ningdong granule on microglia-mediated neuroinflammation in a rat model of Tourette's syndrome.
Topics: Animals; Chemokine CCL2; Corpus Striatum; Disease Models, Animal; Drugs, Chinese Herbal; Haloperidol; Humans; Interleukin-6; Male; Microglia; Nitriles; Rats; Rats, Wistar; Tourette Syndrome; Tumor Necrosis Factor-alpha | 2020 |
Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Topics: Animals; Benzazepines; Cocaine; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Hyperthermia; Ketanserin; Male; Rats; Rats, Wistar; Risperidone; Ritanserin; Serotonin 5-HT2 Receptor Antagonists | 2020 |
Investigation of anti-Parkinson activity of dicyclomine.
Topics: Animals; Dicyclomine; Disease Models, Animal; Dopamine; Haloperidol; Mice; Paraquat; Parkinson Disease, Secondary; Parkinsonian Disorders; Substantia Nigra | 2022 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; Metabolome; Methylazoxymethanol Acetate; Olanzapine; Rats, Sprague-Dawley; Risperidone; Schizophrenia | 2020 |
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Arginine; Behavior, Animal; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Enzyme Inhibitors; Haloperidol; Male; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Peptide Fragments; Proteins; Rats; Rats, Wistar; Schizophrenia | 2021 |
Synergistic interaction between haloperidol and gabapentin in a model of neuropathic nociception in rat.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Gabapentin; Haloperidol; Hyperalgesia; Male; Nociception; Nociceptive Pain; Rats, Wistar; Receptors, sigma; Sciatica; Sigma-1 Receptor; Signal Transduction | 2021 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Abdominal Fat; Methylazoxymethanol Acetate; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Proteomics; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats.
Topics: Animals; Anxiety; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Male; Rats; Rats, Wistar | 2020 |
Haloperidol potentiates antinociceptive effects of morphine and disrupt opioid tolerance.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Drug Tolerance; Haloperidol; Male; Morphine; Neuralgia; Nociception; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Signal Transduction; Time Factors | 2021 |
Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesias; Flavanones; Haloperidol; Humans; Inflammation Mediators; Male; Rats; Rats, Wistar; Tardive Dyskinesia | 2021 |
Discovery and optimization of a novel CNS penetrant series of mGlu
Topics: Allosteric Regulation; Animals; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Haloperidol; Mice; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Receptors, Metabotropic Glutamate; Structure-Activity Relationship | 2021 |
Two novel mouse models mimicking minor deletions in 22q11.2 deletion syndrome revealed the contribution of each deleted region to psychiatric disorders.
Topics: 22q11 Deletion Syndrome; Animals; Base Sequence; Behavior, Animal; Circadian Rhythm; Conditioning, Classical; Cues; Disease Models, Animal; Electroencephalography; Electromyography; Fear; Gene Dosage; Gene Expression Regulation; Haloperidol; Male; Memory; Mental Disorders; Mice, Inbred C57BL; Motor Activity; Prepulse Inhibition; RNA, Messenger; Sensory Gating; Sequence Deletion; Sleep; Social Behavior; Wakefulness | 2021 |
Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Haloperidol; Phenotype; Rats; Rotenone; Schizophrenia | 2021 |
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis.
Topics: Animals; Antipsychotic Agents; Autophagy; Autophagy-Related Proteins; Axons; Biomarkers; Clozapine; Cytokines; Demyelinating Diseases; Disease Models, Animal; Glucose; Haloperidol; Inflammation; Interleukin-1beta; Mitochondria; Mitophagy; Models, Biological; Motor Activity; Multiple Sclerosis; Myelin Basic Protein; Myelin Sheath; Stress, Physiological; Tumor Necrosis Factor-alpha | 2021 |
Obesity Potentiates the Risk of Drug-Induced Long QT Syndrome - Preliminary Evidence from WNIN/Ob Spontaneously Obese Rat.
Topics: Adiposity; Animals; Antipsychotic Agents; Cardiomegaly; Disease Models, Animal; Female; Haloperidol; Heart Rate; Hydroxyproline; Long QT Syndrome; Myocytes, Cardiac; Natriuretic Peptide, Brain; Obesity; Protein Carbonylation; Rats, Inbred Strains; Risk Assessment; Risk Factors; Time Factors | 2021 |
Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats.
Topics: Animals; Antioxidants; Behavior, Animal; Catalase; Corpus Striatum; Disease Models, Animal; Glutathione Peroxidase; Haloperidol; Lipid Peroxidation; Male; Malondialdehyde; Motor Activity; Oxidative Stress; Rats; Rats, Wistar; Rice Bran Oil; Superoxide Dismutase; Tardive Dyskinesia | 2017 |
Novel therapeutic approaches of natural oil from black seeds and its underlying mechanisms against kidney dysfunctions in haloperidol-induced male rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Electrolytes; Haloperidol; Kidney; Lipid Peroxidation; Male; Nigella sativa; Oils, Volatile; Rats; Rats, Wistar; Renal Insufficiency; Seeds | 2017 |
The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression.
Topics: Affect; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Cell Survival; Clozapine; Depression; Disease Models, Animal; Haloperidol; Hippocampus; Male; Neurogenesis; Neuronal Plasticity; Prefrontal Cortex; Rats; Rats, Wistar; Swimming | 2017 |
Comparable impediment of cognitive function in female and male rats subsequent to daily administration of haloperidol after traumatic brain injury.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain Injuries, Traumatic; Cognition; Disease Models, Animal; Estrous Cycle; Female; Haloperidol; Male; Motor Activity; Neurologic Examination; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Retention, Psychology; Sex Characteristics; Spatial Learning; Time Factors | 2017 |
An ethanolic extract of Desmodium adscendens exhibits antipsychotic-like activity in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Ethanol; Fabaceae; Female; Haloperidol; Mice; Mice, Inbred ICR; Motor Activity; Phytotherapy; Plant Extracts | 2017 |
Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Catalepsy; Chlorpromazine; Disease Models, Animal; Haloperidol; Herb-Drug Interactions; Hypnotics and Sedatives; Mice, Inbred BALB C; Mice, Inbred ICR; Motor Activity; Phytotherapy; Plant Extracts; Psychotic Disorders | 2017 |
Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Dendritic Spines; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopaminergic Neurons; Female; Haloperidol; Male; Mice; Mice, Inbred ICR; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects; Risperidone; Social Behavior; Valproic Acid | 2017 |
Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits.
Topics: Animals; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; CA1 Region, Hippocampal; Clozapine; Developmental Disabilities; Disease Models, Animal; Female; Folic Acid; Haloperidol; Humans; Male; Methionine; Mice; Neurogenesis; Neuronal Plasticity; One-Carbon Group Transferases; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects; Schizophrenia; Stereotyped Behavior; Tetrahydrofolates | 2018 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Haloperidol; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Olanzapine; Piperazines; Quinuclidines; Schizophrenia; Spatial Learning; Thiazoles; Treatment Outcome | 2017 |
Awakenings in rats by ultrasounds: A new animal model for paradoxical kinesia.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Radiation; Exploratory Behavior; Haloperidol; Male; Rats; Rats, Wistar; Treatment Outcome; Ultrasonic Therapy; Wakefulness | 2018 |
Role of dopamine on functional recovery in the contralateral hemisphere after focal stroke in the somatosensory cortex.
Topics: Animals; Aripiprazole; Brain; Disease Models, Animal; Dopamine; Functional Laterality; Haloperidol; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Recovery of Function; Somatosensory Cortex; Stroke | 2018 |
Spontaneous recovery of traumatic brain injury-induced functional deficits is not hindered by daily administration of lorazepam.
Topics: Animals; Antipsychotic Agents; Brain Injuries, Traumatic; Cognition; Conditioning, Psychological; Disease Models, Animal; Haloperidol; Lorazepam; Male; Motor Activity; Rats, Sprague-Dawley; Recovery of Function | 2018 |
Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Biological Products; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Drug Therapy, Combination; Drugs, Chinese Herbal; Haloperidol; Male; Phytotherapy; Rats, Sprague-Dawley; Schizophrenia | 2018 |
Antiallergic and antihistaminic actions of Ceasalpinia bonducella seeds: Possible role in treatment of asthma.
Topics: Acetates; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Caesalpinia; Catalepsy; Cell Degranulation; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Eosinophilia; Female; Guinea Pigs; Haloperidol; Histamine Antagonists; Ileum; Lethal Dose 50; Leukocytosis; Male; Mast Cells; Mice; Milk; Muscle Relaxation; Muscle, Smooth; Phytotherapy; Plant Extracts; Plants, Medicinal; Receptors, Adrenergic, beta-2; Seeds; Solvents; Time Factors | 2018 |
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesias; Glutamates; Haloperidol; Lipid Peroxidation; Male; Rats; Rats, Wistar; Tardive Dyskinesia | 2018 |
Haloperidol-induced catalepsy is ameliorated by deep brain stimulation of the inferior colliculus.
Topics: Animals; Antipsychotic Agents; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Inferior Colliculi; Rats | 2018 |
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
Topics: Administration, Oral; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Benzodiazepines; Catalepsy; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Drug Therapy, Combination; Haloperidol; Humans; Male; Methamphetamine; Mice; Mice, Inbred ICR; Neurons; Olanzapine; Phosphodiesterase Inhibitors; Prolactin; Pyrazoles; Pyridazines; Rats; Rats, Sprague-Dawley; Synaptic Potentials; Treatment Outcome | 2018 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Disease Models, Animal; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Flavonoids; Haloperidol; Ketamine; Male; Memory, Short-Term; Mice; NADPH Oxidases; Risperidone; Schizophrenia; Stereotyped Behavior; Superoxide Dismutase; Swimming | 2018 |
Paradoxical kinesia induced by appetitive 50-kHz ultrasonic vocalizations in rats depends on glutamatergic mechanisms in the inferior colliculus.
Topics: Animals; Appetitive Behavior; Catalepsy; Diazepam; Disease Models, Animal; GABA Modulators; Glutamic Acid; Haloperidol; Inferior Colliculi; Male; N-Methylaspartate; Neurotransmitter Agents; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Ultrasonics; Vocalization, Animal | 2018 |
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neurons; Parkinsonian Disorders; Varenicline | 2018 |
Altered dopaminergic regulation of the dorsal striatum is able to induce tic-like movements in juvenile rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Down-Regulation; Haloperidol; Male; Motor Activity; Oxidopamine; Phenotype; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Tourette Syndrome | 2018 |
Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Compounding; Haloperidol; Male; Nanoparticles; Oxidative Stress; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Up-Regulation | 2018 |
Albizia zygia root extract exhibits antipsychotic-like properties in murine models of schizophrenia.
Topics: Albizzia; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Cognition; Disease Models, Animal; Exploratory Behavior; Haloperidol; Male; Mice, Inbred ICR; Motor Activity; Phytotherapy; Plant Extracts; Plant Roots; Plants, Medicinal; Schizophrenia; Schizophrenic Psychology; Social Behavior | 2018 |
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Psychotic Disorders; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Failure | 2018 |
State-dependent effects of the D
Topics: Animals; Apomorphine; Aripiprazole; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopaminergic Neurons; Electroencephalography; Haloperidol; Male; Methylazoxymethanol Acetate; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Ventral Tegmental Area | 2019 |
Na
Topics: Animals; Chlorpromazine; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Genes, fos; Haloperidol; Impulsive Behavior; Infusions, Intraventricular; Locomotion; Male; Mice; Mice, Inbred C57BL; Neuroglia; Ouabain; Prefrontal Cortex; Receptors, Dopamine D2; Signal Transduction; Sodium-Potassium-Exchanging ATPase | 2019 |
Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Ascorbic Acid; Behavior, Animal; Biological Availability; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Humans; Losartan; Male; Parkinsonian Disorders; Rats; Rats, Wistar; Renin-Angiotensin System | 2018 |
Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.
Topics: Animals; Antipsychotic Agents; Apathy; Behavior, Animal; Biperiden; Cognitive Dysfunction; Disease Models, Animal; Haloperidol; Mice; Mice, Inbred C57BL; Motivation; Muscarinic Antagonists; Psychomotor Performance; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Scopolamine; Tropicamide | 2019 |
Impact of nuclear distribution element genes in the typical and atypical antipsychotics effects on nematode Caenorhabditis elegans: Putative animal model for studying the pathways correlated to schizophrenia.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Behavior, Animal; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Carrier Proteins; Clozapine; Disease Models, Animal; Haloperidol; Movement; Neurotransmitter Agents; Pharynx; Proton Magnetic Resonance Spectroscopy; Reproducibility of Results; Reproduction; Schizophrenia; Serotonin | 2019 |
Influence of aversive stimulation on haloperidol-induced catalepsy in rats.
Topics: Affect; Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopamine Antagonists; Fear; Haloperidol; Male; Parkinson Disease; Rats; Rats, Wistar | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Hippocampus; Methylazoxymethanol Acetate; Mice; Motor Activity; Pregnancy; Prenatal Exposure Delayed Effects; Prepulse Inhibition; Risperidone; Schizophrenia | 2019 |
High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation.
Topics: Actins; Animals; Calcium; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Drug Repositioning; Endoplasmic Reticulum Stress; Fibrosis; Haloperidol; Humans; Intravital Microscopy; Lung; Mice; Myocardium; Myofibroblasts; Optical Imaging; Primary Cell Culture; Receptor, Notch1; Receptors, sigma; RNA Interference; RNA, Small Interfering; Sigma-1 Receptor; Signal Transduction | 2019 |
Role of Aqueous Extract of the Wood Ear Mushroom, Auricularia polytricha (Agaricomycetes), in Avoidance of Haloperidol-lnduced Catalepsy via Oxidative Stress in Rats.
Topics: Animals; Antipsychotic Agents; Basidiomycota; Catalepsy; Disease Models, Animal; Fruiting Bodies, Fungal; Haloperidol; Lipid Peroxidation; Male; Oxidative Stress; Plant Extracts; Protective Agents; Rats; Rats, Wistar; Water | 2019 |
Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment.
Topics: Animals; Behavior, Animal; Cognition; Discrimination Learning; Disease Models, Animal; Exploratory Behavior; Female; Haloperidol; Mice; Mice, Inbred C57BL; Motor Activity; Reversal Learning; Reward; Schizophrenia; Social Environment | 2019 |
Assessing Reality Testing in Mice Through Dopamine-Dependent Associatively Evoked Processing of Absent Gustatory Stimuli.
Topics: Animals; Antipsychotic Agents; Association Learning; Auditory Perception; Behavior, Animal; Cerebral Cortex; Conditioning, Classical; Delusions; Disease Models, Animal; Dopamine; Hallucinations; Haloperidol; Mice; Mice, Transgenic; Nerve Tissue Proteins; Reality Testing; Reward; Social Isolation; Taste Perception | 2020 |
Isoallopregnanolone reduces tic-like behaviours in the D1CT-7 mouse model of Tourette syndrome.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Finasteride; Haloperidol; Housing, Animal; Male; Mice; Pregnanolone; Tics; Tourette Syndrome | 2020 |
Differential effects of antipsychotic drugs on contrast response functions of retinal ganglion cells in wild-type Sprague-Dawley rats and P23H retinitis pigmentosa rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Male; Photic Stimulation; Rats; Rats, Sprague-Dawley; Retina; Retinal Ganglion Cells; Retinitis Pigmentosa | 2019 |
Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Male; Mastication; Rats; Rats, Wistar; Tardive Dyskinesia | 2019 |
Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Delta Rhythm; Dibenzocycloheptenes; Disease Models, Animal; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Rats; Rats, Sprague-Dawley; Schizophrenia | 2019 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome | 2013 |
Unique pharmacological actions of atypical neuroleptic quetiapine: possible role in cell cycle/fate control.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Astrocytes; Cell Cycle; Dibenzothiazepines; Disease Models, Animal; Frontal Lobe; Gene Expression; Haloperidol; In Situ Hybridization; Male; Methamphetamine; Mice; Neurons; Oligodendroglia; p21-Activated Kinases; Principal Component Analysis; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Schizophrenia | 2013 |
Involvement of transmitters in the anxiolytic action of urocortin 3 in mice.
Topics: Analysis of Variance; Animals; Anxiety; Atropine; Bicuculline; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Maze Learning; Methysergide; Mice; Naloxone; Neurotransmitter Agents; Propranolol; Time Factors; Urocortins | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2013 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; Haloperidol; L-Lactate Dehydrogenase; Male; Mouth; Movement Disorders; Oxidative Stress; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones | 2013 |
Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free Radical Scavengers; Ginkgo biloba; Haloperidol; Male; Mastication; Plant Extracts; Rats; Rats, Sprague-Dawley; Vitamin E | 2013 |
[Changes in neuroglial interactions in the cerebral nigrostriatal structures in a model of dopamine system dysfunction].
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine Antagonists; Haloperidol; Neuroglia; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2013 |
Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Chromatography, Liquid; Disease Models, Animal; Haloperidol; Male; Mastication; Mice; Mice, Inbred C57BL; Phenols; Propanols; Species Specificity; Statistics, Nonparametric; Tandem Mass Spectrometry | 2013 |
Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
Topics: Adenosine A2 Receptor Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Cebus; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Motor Activity; Phosphodiesterase Inhibitors; Piperazines; Pyrazoles; Pyrimidines; Quinolines; Quinolones; Triazoles | 2014 |
Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison.
Topics: Animals; Disease Models, Animal; Dopamine Antagonists; Electromyography; Haloperidol; Jaw; Male; Motor Activity; Movement; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tremor; Ventral Striatum | 2014 |
Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Sensitization; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Male; Mice; Motor Activity; Piperazines; Quinolones; Thiazoles | 2014 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Haloperidol; Male; Motor Activity; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Reserpine; Time Factors | 2013 |
Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Area Under Curve; Brain; Clozapine; Disease Models, Animal; Dissociative Disorders; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Ketamine; Male; Oxygen; Rats; Tissue Distribution | 2014 |
Evaluation of the antipsychotic potential of aqueous fraction of Securinega virosa root bark extract in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Euphorbiaceae; Female; Grooming; Haloperidol; Male; Medicine, African Traditional; Methanol; Mice; Phytotherapy; Plant Bark; Plant Extracts; Plant Roots; Solvents; Stereotyped Behavior; Swimming; Water | 2014 |
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Diazepam; Disease Models, Animal; Dopamine; Dopamine Agents; Dopaminergic Neurons; Drug Interactions; Female; GABA Agonists; Haloperidol; Hippocampus; Imidazoles; Locomotion; Male; Methylazoxymethanol Acetate; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Schizophrenia; Sodium Chloride; Substance Withdrawal Syndrome; Ventral Tegmental Area | 2014 |
The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Cholinergic Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Male; Pirenzepine; Protein Binding; Rats; Rats, Wistar; Reaction Time; Receptors, Muscarinic; Time Factors | 2014 |
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesias; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Oxidopamine; Parkinson Disease; Receptors, G-Protein-Coupled; Tyrosine 3-Monooxygenase | 2014 |
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Endocannabinoids; Haloperidol; Male; Mastication; Movement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome | 2014 |
Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Clozapine; Disease Models, Animal; Dopamine Antagonists; Enkephalins; Female; Haloperidol; Iodine Radioisotopes; Movement Disorders; Neurons; Ovariectomy; Protein Binding; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulpiride; Tetrahydronaphthalenes; Up-Regulation | 2014 |
Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Antagonists; Dronabinol; Gait Disorders, Neurologic; Hallucinogens; Haloperidol; Male; Prepulse Inhibition; Psychoacoustics; Rats; Rats, Sprague-Dawley; Time Factors | 2014 |
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Topics: Amino Acid Transport System X-AG; Anilides; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Corpus Striatum; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dopamine Antagonists; Excitatory Amino Acid Agents; Globus Pallidus; Glutamic Acid; Haloperidol; Male; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, Metabotropic Glutamate; Synapses; Synaptic Transmission; Tissue Culture Techniques | 2014 |
Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; DNA Methylation; Gene Expression; Haloperidol; Male; Neurotransmitter Agents; Nucleus Accumbens; Prefrontal Cortex; Promoter Regions, Genetic; Rats, Inbred SHR; Risperidone; Schizophrenia | 2014 |
The sigma-1 receptor agonist 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) protects against newborn excitotoxic brain injury by stabilizing the mitochondrial membrane potential in vitro and inhibiting microglial activation in vivo.
Topics: Animals; Animals, Newborn; Apoptosis; Apoptosis Inducing Factor; Brain Injuries; Caspase 3; Disease Models, Animal; Excitatory Amino Acid Agonists; Glutamic Acid; Glycoproteins; Haloperidol; Hippocampus; Ibotenic Acid; Membrane Potential, Mitochondrial; Mice; Microglia; Neurons; Receptors, sigma; Sigma-1 Receptor; Statistics, Nonparametric | 2014 |
Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Anxiety; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Immobility Response, Tonic; Male; Maze Learning; Mice; Oligopeptides; Phenoxybenzamine; Prazosin; Serotonin Agents; Swimming | 2014 |
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Lipid Peroxidation; Male; Mice; Motor Activity; Parkinsonian Disorders; Tea | 2015 |
Reversal of haloperidol induced motor deficits in rats exposed to repeated immobilization stress.
Topics: Adaptation, Psychological; Animals; Brain; Disease Models, Animal; Haloperidol; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Restraint, Physical; Stress, Psychological; Time Factors | 2014 |
Haloperidol-induced extra pyramidal symptoms attenuated by imipramine in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Imipramine; Male; Mastication; Motor Activity; Psychomotor Performance; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Rotarod Performance Test; Time Factors | 2014 |
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Haloperidol; Hippocampus; Male; Memory, Short-Term; Neuronal Plasticity; Olanzapine; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Schizophrenia; Spatial Learning | 2014 |
Dual regulating effects of gastrodin on extracellular dopamine concentration in rats models of Tourette's syndrome.
Topics: Animals; Apomorphine; Benzyl Alcohols; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Down-Regulation; Glucosides; Haloperidol; Homovanillic Acid; Male; Nitriles; Rats; Stereotyped Behavior; Tourette Syndrome; Up-Regulation | 2015 |
Haloperidol treatment at pre-exposure phase reduces the disturbance of latent inhibition in rats with neonatal ventral hippocampus lesions.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Haloperidol; Hippocampus; Lidocaine; Motor Activity; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizotypal Personality Disorder; Taste | 2014 |
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Glycine; Glycine Plasma Membrane Transport Proteins; Haloperidol; Imipramine; Locomotion; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sarcosine; Schizophrenia; Serine; Swimming | 2015 |
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice.
Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Central Nervous System Stimulants; Choline O-Acetyltransferase; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Extracellular Space; Haloperidol; Levodopa; Locomotion; Mice, Inbred C57BL; Piperazines; Psychomotor Agitation; Thiazoles | 2015 |
-NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Calcium; Cognition Disorders; Disease Models, Animal; Disease Progression; Haloperidol; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Motor Cortex; Parkinsonian Disorders; Phenotype; Receptors, Calcitriol; Receptors, N-Methyl-D-Aspartate | 2015 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epilepsy; Haloperidol; Mental Disorders; Olanzapine; Quetiapine Fumarate; Rats; Risperidone; Seizures | 2015 |
Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients?
Topics: Animals; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Inferior Colliculi; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar | 2015 |
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol; Isoindoles; Memory Disorders; Phencyclidine; Piperazines; Piperidines; Pyrimidines; Random Allocation; Rats, Long-Evans; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Urea | 2015 |
Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Atherosclerosis; ATP Binding Cassette Transporter 1; Cells, Cultured; Chemokine CCL2; Chemotaxis; Cholesterol; Diet, Western; Disease Models, Animal; Down-Regulation; Female; Haloperidol; Hyperlipidemias; Liver; Macrophages, Peritoneal; Mice, Knockout; Plaque, Atherosclerotic; Receptors, LDL | 2015 |
Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Dietary Sucrose; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Eating; Fluoxetine; Haloperidol; Imipramine; Lithium Compounds; Male; Motivation; Nucleus Accumbens; Phosphorylation; Rats, Sprague-Dawley; Stress, Psychological | 2015 |
Neuro-anatomic mapping of dopamine D1 receptor involvement in nicotine self-administration in rats.
Topics: Animals; Benzazepines; Brain Mapping; Catheters, Indwelling; Cohort Studies; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Gyrus Cinguli; Haloperidol; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Parietal Lobe; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Self Administration; Tobacco Use Disorder | 2015 |
Inhibition of 14-3-3 Proteins Leads to Schizophrenia-Related Behavioral Phenotypes and Synaptic Defects in Mice.
Topics: 14-3-3 Proteins; Animals; Antipsychotic Agents; Behavior, Animal; Catenins; Cerebral Cortex; Clozapine; Cofilin 1; Delta Catenin; Dendrites; Disease Models, Animal; Dopamine; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Prepulse Inhibition; Proteins; Receptors, Dopamine; Schizophrenia; Schizophrenic Psychology; Synaptic Transmission | 2015 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Basal Ganglia; Binding, Competitive; Catalepsy; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; HEK293 Cells; Humans; Injections, Intraperitoneal; Ligands; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Transfection; Triazoles | 2015 |
Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.
Topics: Animals; Brain; Chemistry, Pharmaceutical; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Drug Delivery Systems; Glutathione; Haloperidol; Indoles; Microscopy, Confocal; Microscopy, Electron, Scanning Transmission; Motor Activity; Nanoparticles; Parkinson Disease; Psychomotor Performance; Radionuclide Imaging; Rats; Rats, Wistar; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2015 |
A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Depression; Disease Models, Animal; Haloperidol; Male; Methionine; Mice; Motor Activity; Pain Threshold; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Sensory Gating; Social Behavior; Stereotyped Behavior; Treatment Outcome | 2015 |
Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Antipsychotic Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Finasteride; Haloperidol; Injections, Intraperitoneal; Male; Nucleus Accumbens; Pregnenolone; Prepulse Inhibition; Random Allocation; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Social Isolation; Stress, Psychological | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal | 2015 |
Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo.
Topics: Animals; Brain; Bromocriptine; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Haloperidol; Hyperprolactinemia; Medicine, Chinese Traditional; Progesterone; Prolactin; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2015 |
Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Gene Expression; Glycine Plasma Membrane Transport Proteins; Haloperidol; Male; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Inbred SHR; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; Schizophrenia | 2015 |
Inhalation of Cedrus atlantica essential oil alleviates pain behavior through activation of descending pain modulation pathways in a mouse model of postoperative pain.
Topics: Administration, Inhalation; Adrenergic alpha-2 Receptor Antagonists; alpha-Methyltyrosine; Analgesics; Animals; Behavior, Animal; Cedrus; Disease Models, Animal; Dopamine Antagonists; Fenclonine; Foot; Haloperidol; Hyperalgesia; Male; Mice; Motor Activity; Naloxone; Narcotic Antagonists; Oils, Volatile; Pain, Postoperative; Phytotherapy; Serotonin Antagonists; Yohimbine | 2015 |
Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms.
Topics: Animals; Anti-Dyskinesia Agents; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Ginkgo biloba; Haloperidol; Immunohistochemistry; Injections, Intraperitoneal; Male; Mastication; Movement Disorders; Plant Extracts; Random Allocation; Rats, Sprague-Dawley; S100 Calcium Binding Protein beta Subunit; Vitamin E | 2016 |
Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
Topics: Amisulpride; Animals; Anti-Dyskinesia Agents; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Essential Tremor; Haloperidol; Harmaline; Imidazoles; Male; Movement; Nitriles; Pramipexole; Pyridines; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulpiride; Tetrahydroisoquinolines; Tetrahydronaphthalenes; Treatment Outcome | 2016 |
LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Ketamine; Male; Memory, Long-Term; Memory, Short-Term; Mice; Piperazines; Recognition, Psychology; Schizophrenia; Time Factors | 2016 |
Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.
Topics: Action Potentials; Animals; Basal Ganglia; Bee Venoms; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Electric Stimulation; Haloperidol; Male; Motor Activity; Motor Cortex; Oxidopamine; Parkinson Disease; Rats, Wistar; Receptors, Dopamine; Substantia Nigra | 2015 |
High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Chronic Disease; Diazepam; Disease Models, Animal; Dominance-Subordination; Fluoxetine; Haloperidol; Hippocampus; Ketamine; Lithium Compounds; Male; Mice, Inbred C57BL; Neural Pathways; Stress, Psychological; Tissue Culture Techniques; Voltage-Sensitive Dye Imaging | 2015 |
Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Domperidone; Dopamine; Dopamine Antagonists; Functional Laterality; Haloperidol; Hypoxia; Male; Motor Activity; Oxidopamine; Parkinson Disease; Plethysmography; Rats; Rats, Wistar; Respiration | 2016 |
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Female; Gene Expression; Haloperidol; Humans; Macaca fascicularis; MafB Transcription Factor; Male; Middle Aged; Neurons; Olanzapine; Parvalbumins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Prefrontal Cortex; Receptor, Fibroblast Growth Factor, Type 1; RNA, Messenger; Schizophrenia; Somatostatin | 2016 |
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Electroencephalography; Haloperidol; Ketamine; Male; Olanzapine; Prepulse Inhibition; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Schizophrenia | 2016 |
High estrogen and chronic haloperidol lead to greater amphetamine-induced BOLD activation in awake, amphetamine-sensitized female rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Estradiol; Female; Haloperidol; Magnetic Resonance Imaging; Ovariectomy; Oxygen; Rats; Rats, Sprague-Dawley; Wakefulness | 2016 |
Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized cata
Topics: Analysis of Variance; Animals; Apomorphine; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Rats, Wistar | 2016 |
Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
Topics: Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Ginkgo biloba; Haloperidol; Male; Mastication; Plant Extracts; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tardive Dyskinesia; Vitamin E | 2016 |
The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Benzofurans; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Drug Synergism; Haloperidol; Male; Prepulse Inhibition; Quinolizidines; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Social Isolation; Statistics, Nonparametric | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Catalepsy; Disease Models, Animal; Dopamine Agonists; Forelimb; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Transfection | 2016 |
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Channelrhodopsins; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; GABAergic Neurons; Gene Expression Regulation; Haloperidol; Male; Mastication; Mecamylamine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Receptors, Dopamine D2; Tardive Dyskinesia | 2016 |
Effects of Antipsychotic Drugs Haloperidol and Clozapine on Visual Responses of Retinal Ganglion Cells in a Rat Model of Retinitis Pigmentosa.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Rats; Retinal Ganglion Cells; Retinitis Pigmentosa | 2016 |
Effect of L-pGlu-(1-benzyl)-l-His-l-Pro-NH
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Ischemia; Catalepsy; Cell Death; Disease Models, Animal; Glucose; Glutamic Acid; Haloperidol; Hippocampus; Inflammation Mediators; Lipid Peroxidation; Male; Memory Disorders; Mice; Models, Biological; Motor Activity; Neurons; Oxygen; PC12 Cells; Rats; Scopolamine; Thyrotropin-Releasing Hormone | 2016 |
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Catalepsy; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Haloperidol; Magnesium; Male; Protein Carbonylation; Rats; Rats, Wistar; Time Factors | 2017 |
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
Topics: alpha-Tocopherol; Animals; Antioxidants; Antipsychotic Agents; bcl-2-Associated X Protein; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Ginkgo biloba; Haloperidol; Injections, Intraperitoneal; Male; Mastication; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley | 2016 |
The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Brain; Cannabinoid Receptor Agonists; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dronabinol; Haloperidol; Hypothyroidism; Imidazoles; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Perchlorates; Phenotype; Potassium Compounds; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2017 |
Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Disease Models, Animal; Disks Large Homolog 4 Protein; Female; Haloperidol; Humans; Male; Mice; Mice, Transgenic; Middle Aged; Nerve Tissue Proteins; Prefrontal Cortex; Protein Isoforms; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA Splice Sites; Schizophrenia | 2017 |
Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain; Disease Models, Animal; Haloperidol; Imipramine; Male; Mastication; Motor Activity; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin and Noradrenaline Reuptake Inhibitors; Tardive Dyskinesia; Time Factors | 2016 |
Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Fenclonine; Gene Expression Regulation; Haloperidol; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Serotonin Antagonists; Serotonin Receptor Agonists; Statistics, Nonparametric | 2008 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Haloperidol; Neurologic Examination; Purines; Pyrimidines; Receptor, Adenosine A2A; Saimiri; Triazoles; Xanthines | 2008 |
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clomipramine; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Haloperidol; Male; Olanzapine; Piperazines; Pyrroles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Thiazepines | 2008 |
Behavioral effects of 1-(m-chlorophenyl)piperazine (m-CPP) in a rat model of tardive dyskinesia.
Topics: Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Eating; Exploratory Behavior; Feeding Behavior; Female; Haloperidol; Mastication; Motor Activity; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Time Factors | 2008 |
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Haloperidol; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Reaction Time; Receptors, Adenosine A2; Receptors, Metabotropic Glutamate; Tricarboxylic Acids; Xanthines | 2008 |
An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Haloperidol; Heart; Heart Rate; In Vitro Techniques; Phenethylamines; Rabbits; Sulfonamides; Torsades de Pointes | 2008 |
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Attention; Cholinergic Antagonists; Clozapine; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Glycine; Haloperidol; Inhibition, Psychological; Male; Physostigmine; Rats; Rats, Wistar; Schizophrenia; Scopolamine | 2009 |
Evaluation of the repeated open-space swim model of depression in the mouse.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cell Proliferation; Chronic Disease; Depression; Desipramine; Diazepam; Disease Models, Animal; Fluoxetine; Food Preferences; Haloperidol; Hindlimb Suspension; Hypnotics and Sedatives; Male; Mice; Motor Activity; Neurons; Swimming | 2008 |
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.
Topics: Age Factors; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Haloperidol; Locomotion; Male; Pregnancy; Prenatal Nutritional Physiological Phenomena; Protein Binding; Protein Deficiency; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Glutamate; Sex Factors | 2008 |
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain; Central Nervous System Stimulants; Clozapine; Disease Models, Animal; Female; Haloperidol; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Polynucleotides; Pregnancy; Prenatal Exposure Delayed Effects; Schizophrenia; Schizophrenic Psychology; Sensory Gating | 2010 |
Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Glutathione Peroxidase; Haloperidol; Male; Malondialdehyde; Mice; Naphthalenes; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Superoxide Dismutase; Thiazoles | 2009 |
Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Basal Ganglia Diseases; Behavior, Animal; Brain; Disease Models, Animal; Haloperidol; Locomotion; Male; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Presynaptic; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Serotonin Syndrome; Time Factors; Up-Regulation | 2008 |
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Catalepsy; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Haloperidol; Humans; Ligands; Molecular Structure; Parkinson Disease; Pyrazoles; Pyrimidines; Rats; Stereoisomerism; Structure-Activity Relationship | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous System Stimulants; Disease Models, Animal; Drug Interactions; Electroencephalography; Evoked Potentials, Auditory; Excitatory Amino Acid Antagonists; Haloperidol; Ketamine; Male; Mice; Mice, Inbred C57BL; Reaction Time; Risperidone; Schizophrenia | 2009 |
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Topics: Acetylcysteine; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Brain; Cognition Disorders; Conditioning, Psychological; Cyclic AMP; Disease Models, Animal; Erythromycin; Exploratory Behavior; Fear; Female; Gene Expression Regulation, Developmental; GTP-Binding Protein alpha Subunits, Gs; Haloperidol; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphodiesterase Inhibitors; Psychophysics; Reflex, Startle; Rolipram; Time Factors | 2009 |
Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Hyperkinesis; Male; Phencyclidine; Rats; Rats, Sprague-Dawley; Time Factors | 2009 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione; Haloperidol; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Posture; Superoxide Dismutase; Swimming | 2009 |
Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estradiol; Estrogens; Female; Haloperidol; Humans; Ovariectomy; Rats; Rats, Wistar; Schizophrenia | 2009 |
Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia; Tissue Distribution | 2009 |
Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.
Topics: Analysis of Variance; Animals; Brain; Capsaicin; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Hyperalgesia; Mice; Morpholines; Motor Activity; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pentazocine; Physical Stimulation; Protein Binding; Radioligand Assay; Reaction Time; Receptors, sigma; Rotarod Performance Test; Sigma-1 Receptor; Tritium | 2009 |
Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats.
Topics: Analysis of Variance; Animals; Chloroquinolinols; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Female; Haloperidol; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Synapses; Ultrasonics; Vocalization, Animal | 2009 |
Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Topics: Animals; Antipsychotic Agents; Blotting, Western; Brain; Disease Models, Animal; Haloperidol; Humans; Middle Aged; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Schizophrenia | 2009 |
Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Behavior; Catalepsy; Cell Line; Disease Models, Animal; Electrophysiological Phenomena; Globus Pallidus; Haloperidol; Humans; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphinic Acids; Rats; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2009 |
Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Behavior, Animal; Benzene Derivatives; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Haloperidol; Male; Mice; Mice, Inbred ICR; Morphine; Motor Activity; Pain; Pain Measurement | 2009 |
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Hyperkinesis; Male; Risperidone; Swine; Swine, Miniature | 2009 |
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Fatty Acids, Omega-3; Haloperidol; Male; Maze Learning; Memory Disorders; Movement Disorders; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Time Factors | 2010 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Forelimb; Functional Laterality; Haloperidol; Male; Microinjections; Motor Cortex; Movement Disorders; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Substantia Nigra; Sympatholytics | 2009 |
Does haloperidol have side effects on histological and stereological structure of the rat kidneys?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Immunohistochemistry; Injections, Intraperitoneal; Kidney; Kidney Cortex; Kidney Diseases; Kidney Glomerulus; Kidney Medulla; Microscopy; Organ Size; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values | 2009 |
The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats.
Topics: Aging; Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopamine Antagonists; Frontal Lobe; Haloperidol; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Social Isolation | 2010 |
Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain Ischemia; Corpus Striatum; Disease Models, Animal; Disks Large Homolog 4 Protein; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Nerve Degeneration; Neurons; Nitric Oxide Synthase Type I; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Swine | 2010 |
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Apomorphine; Benzhydryl Compounds; Catalepsy; Disease Models, Animal; Haloperidol; Male; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Reaction Time; Receptors, Metabotropic Glutamate; Stereotyped Behavior | 2010 |
The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Conditioning, Operant; Conflict, Psychological; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Electroshock; Excitatory Amino Acid Antagonists; GABA Agents; Haloperidol; Male; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, GABA-A; Reinforcement Schedule; Reproducibility of Results; Serotonin Receptor Agonists | 2010 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Narcotic Antagonists; Neuropharmacology; Nociceptin; Nociceptin Receptor; Opioid Peptides; Parkinsonian Disorders; Piperidines; Receptors, Opioid; Substantia Nigra; Synaptic Transmission | 2010 |
A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.
Topics: Amphetamine; Animals; Bupropion; Clozapine; Conditioning, Psychological; Disease Models, Animal; Dopamine Agonists; Dopamine Uptake Inhibitors; Drug Interactions; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred C57BL; Neural Inhibition; Phosphodiesterase 4 Inhibitors; Piperazines; Rolipram; Schizophrenic Psychology | 2010 |
Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension.
Topics: Analysis of Variance; Animals; Blood Pressure; Bradykinin B1 Receptor Antagonists; Brain; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Hypertension; Male; Raclopride; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Bradykinin B1 | 2010 |
Prefrontal inositol triphosphate is molecular correlate of working memory in nonhuman primates.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium; Calcium Signaling; Central Nervous System Stimulants; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; GTP-Binding Protein alpha Subunits, Gq-G11; Haloperidol; Inositol 1,4,5-Trisphosphate; Macaca mulatta; Memory Disorders; Memory, Short-Term; Phospholipases; Prefrontal Cortex; Receptors, Dopamine D1; Recovery of Function | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Extracellular Space; Haloperidol; Infusion Pumps, Implantable; Injections, Subcutaneous; Male; Parkinson Disease; Parkinsonian Disorders; Photoperiod; Pramipexole; Rats; Rats, Wistar; Reserpine; Time Factors | 2010 |
The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dibenzothiazepines; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloperidol; Humans; Male; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin Antagonists; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Statistics as Topic; Time Factors | 2011 |
Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?
Topics: Amphetamine; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogens; Female; Haloperidol; Inhibition, Psychological; Ovariectomy; Psychotic Disorders; Rats; Rats, Wistar; Statistics, Nonparametric; Water Deprivation | 2010 |
Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats.
Topics: Animals; Antipsychotic Agents; Cell Proliferation; Disease Models, Animal; Female; Haloperidol; Hippocampus; Male; Maternal-Fetal Exchange; Pregnancy; Rats; Rats, Sprague-Dawley; Schizophrenia; Vitamin D Deficiency | 2010 |
Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia.
Topics: Animals; Benzoxazoles; Cerebral Cortex; Conditioning, Operant; Corticosterone; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drinking; Drug Synergism; Haloperidol; Intracellular Signaling Peptides and Proteins; Male; Naphthyridines; Neuropeptides; Orexins; Psychotic Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Urea | 2010 |
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.
Topics: Adrenergic Agents; Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Female; Gene Expression Regulation; Haloperidol; Humans; Male; Microdialysis; Middle Aged; Nociceptin; Opioid Peptides; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Young Adult | 2010 |
Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cell Count; Dependovirus; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Fluoxetine; Food Preferences; Gene Expression Regulation; Haloperidol; Immobility Response, Tonic; Mice; Mice, Knockout; Mood Disorders; Nucleus Accumbens; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D2; Receptors, Retinoic Acid; Retinoid X Receptor gamma; RNA, Messenger; Serotonin; Signal Transduction | 2010 |
The effects of clozapine on quinpirole-induced non-regulatory drinking and prepulse inhibition disruption in rats.
Topics: Animals; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic Factor; Clozapine; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drinking; Gene Expression Regulation; Haloperidol; Male; Proto-Oncogene Proteins c-fos; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2010 |
Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Entopeduncular Nucleus; Exploratory Behavior; Functional Laterality; Haloperidol; Male; Mastication; Movement Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus; Time Factors | 2011 |
Neonatal ventral hippocampus lesion induces increase in nitric oxide [NO] levels which is attenuated by subchronic haloperidol treatment.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Drug Administration Schedule; Female; Haloperidol; Hippocampus; Male; Nitric Oxide; Rats; Rats, Sprague-Dawley; Schizophrenia | 2010 |
Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Isoindoles; Male; Motor Activity; Piperazines; Pyrimidines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Schizophrenia; Sensory Gating; Serotonin Receptor Agonists | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Ketamine; Male; Mice; Motor Activity; Psychotic Disorders; Random Allocation; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Swimming | 2011 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Extrapyramidal Tracts; Galantamine; Haloperidol; Male; Mecamylamine; Motor Activity; Nicotinic Antagonists; Rats; Rats, Wistar; Receptors, Muscarinic; Risperidone; Schizophrenia; Scopolamine | 2011 |
Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Benzhydryl Compounds; Discrimination, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Executive Function; Haloperidol; Male; Modafinil; Neuropsychological Tests; Phencyclidine; Rats; Recombinant Proteins; Reward; Schizophrenia; Schizophrenic Psychology | 2010 |
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Behavioral Symptoms; Disease Models, Animal; Dizocilpine Maleate; Haloperidol; In Situ Nick-End Labeling; Inhibition, Psychological; Male; Methamphetamine; Microdialysis; Motor Activity; Neuroprotective Agents; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia | 2011 |
Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Globus Pallidus; Haloperidol; Male; Neurotensin; Parkinsonian Disorders; Rats; Rats, Wistar | 2010 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.
Topics: Alkaloids; Analysis of Variance; Animals; Apoptosis; Behavior, Animal; Benzodioxoles; Caspase 3; Colorimetry; Curcumin; Cytokines; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Haloperidol; Inflammation; Male; Neuroprotective Agents; Neurotoxicity Syndromes; Neurotransmitter Agents; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Wistar; Statistics as Topic; Thiobarbituric Acid Reactive Substances | 2011 |
Cholinergic depletion in the nucleus accumbens: effects on amphetamine response and sensorimotor gating.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Choline O-Acetyltransferase; Cholinergic Agents; Disease Models, Animal; Dopamine; Haloperidol; Immunotoxins; Male; Motor Activity; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Reflex, Startle; Ribosome Inactivating Proteins, Type 1; Saporins; Sensory Gating | 2011 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chemical Phenomena; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Nanocapsules; Polysorbates; Rats; Rats, Wistar; Schizophrenia; Stereotyped Behavior | 2011 |
Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Topics: Animals; Basal Ganglia Diseases; Carya; Catalepsy; Disease Models, Animal; Haloperidol; Male; Movement Disorders; Nuts; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Reserpine | 2011 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism | 2011 |
Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Clomipramine; Compulsive Behavior; Conditioning, Operant; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drinking Behavior; Haloperidol; Male; Piperazines; Quinolones; Quinpirole; Rats; Rats, Sprague-Dawley | 2011 |
Characterizing the spontaneous blink generator: an animal model.
Topics: Adult; Animals; Apomorphine; Blinking; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dry Eye Syndromes; Electric Stimulation; Electromyography; Female; Fourier Analysis; Functional Laterality; Haloperidol; Humans; Magnetics; Male; Middle Aged; Rats; Time Factors; Trigeminal Nerve; Young Adult | 2011 |
Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model.
Topics: Animals; Basal Ganglia Diseases; Disease Models, Animal; Female; Gene Expression Regulation; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; RGS Proteins | 2012 |
Behavioral changes induced by long-term proline exposure are reversed by antipsychotics in zebrafish.
Topics: 1-Pyrroline-5-Carboxylate Dehydrogenase; Amino Acid Metabolism, Inborn Errors; Animals; Antipsychotic Agents; Anxiety; Disease Models, Animal; Drug Interactions; Female; Haloperidol; Locomotion; Male; Proline; Proline Oxidase; Social Behavior; Sulpiride; Time Factors; Zebrafish | 2012 |
The effect of haloperidol on maternal behavior in WAG/Rij rats and its consequences in the offspring.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anti-Dyskinesia Agents; Brain Waves; Disease Models, Animal; Electroencephalography; Epilepsy, Absence; Exploratory Behavior; Female; Haloperidol; Male; Maternal Behavior; Maze Learning; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
Topics: Alkaloids; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Facial Muscles; Glutathione; Haloperidol; Lipid Peroxidation; Male; Murraya; Nerve Tissue Proteins; Neurons; Oxidoreductases; Phytotherapy; Plant Extracts; Plant Leaves; Prosencephalon; Rats; Rats, Wistar | 2012 |
An animal model to study the molecular basis of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apoptosis; Behavior, Animal; Caspase 3; Clozapine; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Movement Disorders; Pregnatrienes; Rats; Rats, Wistar | 2012 |
Effects of sertraline on experimental mouse models of psychosis.
Topics: Animals; Antidepressive Agents; Apomorphine; Catalepsy; Dextroamphetamine; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Haloperidol; Mice; Motor Activity; Psychotic Disorders; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors | 2012 |
Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Topics: Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Fluorenes; Haloperidol; Male; Motor Activity; Naphthalenes; Piperazines; Pyrrolidines; Random Allocation; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D3; Spatial Behavior; Time Factors | 2012 |
Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment.
Topics: Aged; Alleles; Animals; Antipsychotic Agents; Cerebellum; Clozapine; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 3; Excitatory Amino Acid Transporter 4; Female; Gene Expression Regulation; Haloperidol; Humans; Male; Middle Aged; Neuregulin-1; Polymorphism, Single Nucleotide; Rats; Rats, Sprague-Dawley; Risk Factors; Schizophrenia | 2013 |
Sedative, antiepileptic and antipsychotic effects of Viscum album L. (Loranthaceae) in mice and rats.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Epilepsy; Female; Haloperidol; Hypnotics and Sedatives; Isoniazid; Male; Mice; Motor Activity; Phytotherapy; Plant Extracts; Plant Leaves; Rats; Rats, Wistar; Sleep; Viscum album | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2013 |
Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis.
Topics: Animals; Antigens, Nuclear; Apoptosis; Cell Nucleus; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dizocilpine Maleate; Gene Expression Profiling; Gene Expression Regulation; Haloperidol; Hippocampus; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neurons; Oligonucleotide Array Sequence Analysis; Proliferating Cell Nuclear Antigen; Psychoses, Substance-Induced; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2012 |
Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Topics: Animals; Anisoles; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Imidazolines; Isoenzymes; Kinetics; Male; Methysergide; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Piperazines; Pyridines | 2012 |
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Topics: Aging; Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Histamine; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred BALB C; Parkinson Disease; Time Factors | 2012 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Forelimb; Glycine; Haloperidol; Injections, Intraventricular; Male; Neostriatum; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Metabotropic Glutamate; Reserpine; Time Factors | 2013 |
Effect of zinc in animal models of anxiety, depression and psychosis.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Agents; Chlorides; Depression; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Freezing Reaction, Cataleptic; Haloperidol; Injections, Intraperitoneal; Male; Maze Learning; Mice; Motor Activity; Psychotic Disorders; Rats; Rats, Wistar; Swimming; Zinc Compounds | 2012 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Immobility Response, Tonic; Ketamine; Male; Motor Activity; Rats; Rats, Wistar; Reproducibility of Results; Risperidone; Schizophrenia; Swimming | 2012 |
Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Frontal Lobe; Haloperidol; Hippocampus; Male; Mice; Motor Activity; Presynaptic Terminals; Recognition, Psychology; Schizophrenia; Synaptophysin; Synaptosomal-Associated Protein 25 | 2012 |
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocaine; Conditioning, Operant; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Electroencephalography; Hallucinogens; Haloperidol; Humans; Macaca fascicularis; Magnetic Resonance Imaging; Male; Mental Recall; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microinjections; Motor Activity; Mutation; Olanzapine; Oocytes; Oxazoles; Phencyclidine; Phenethylamines; Protein Binding; Pyrrolidinones; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Reinforcement, Psychology; Schizophrenia; Swimming; Telemetry; Tritium; Xenopus | 2013 |
A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Dark Adaptation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; GABA Antagonists; Haloperidol; Larva; Lidocaine; Pentylenetetrazole; Seizures; Video Recording; Zebrafish | 2012 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Isoindoles; Lurasidone Hydrochloride; Phencyclidine; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Thiazoles; Urea | 2012 |
A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Cell Cycle Proteins; Clozapine; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Haloperidol; Male; Mice; Mice, Inbred C57BL; Microtubule Proteins; Nerve Tissue Proteins; Neurons; Oligonucleotide Array Sequence Analysis; Organ Specificity; Pilot Projects; RNA, Messenger; Schizophrenia | 2012 |
Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.
Topics: 5,7-Dihydroxytryptamine; Amphetamines; Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Benzylamines; Carbon Isotopes; Chromatography, High Pressure Liquid; Deep Brain Stimulation; Disease Models, Animal; Electrochemical Techniques; Entopeduncular Nucleus; Exploratory Behavior; Fluoxetine; Haloperidol; Hydroxyindoleacetic Acid; Male; Mastication; Microdialysis; Movement Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Subthalamic Nucleus | 2012 |
Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia.
Topics: Animals; Bromocriptine; Cell Line; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Estradiol; Female; Glycyrrhiza; Haloperidol; Herb-Drug Interactions; Hyperprolactinemia; Metoclopramide; Paeonia; PC12 Cells; Phytotherapy; Plant Extracts; Progesterone; Prolactin; Rabbits; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2012 |
Antifibrotic and anti-inflammatory activity of a neuroleptic drug on the model of pulmonary fibrosis.
Topics: Administration, Inhalation; Animals; Antipsychotic Agents; Bleomycin; Cell Differentiation; Connective Tissue; Disease Models, Animal; Haloperidol; Hematopoietic Stem Cells; Inflammation; Lung; Lymphocyte Count; Lymphocytes; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis | 2012 |
[Morphochemical characteristics of hippocampal neuron's response to the hypofunction of the dopaminergic system].
Topics: Animals; Anti-Dyskinesia Agents; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Cell Nucleus; Cytoplasm; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Haloperidol; Parkinson Disease; Pyramidal Cells; Rats; Rats, Inbred Strains | 2012 |
Blood-brain barrier unlocked.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Blood-Brain Barrier; Catalepsy; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Haloperidol; Hydrogen Peroxide; Hypothalamus; Isotope Labeling; Male; Motor Activity; Rats; Rats, Wistar; Reactive Oxygen Species; Tritium | 2012 |
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Down-Regulation; Hallucinogens; Haloperidol; Lysergic Acid Diethylamide; Male; Mice; Mice, 129 Strain; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Time Factors | 2013 |
Differential effects of antipsychotics on lateral bias and social attention in female rats.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Functional Laterality; Haloperidol; Rats; Rats, Long-Evans; Social Behavior; Sulpiride | 2013 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psychological; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Haloperidol; Male; Olanzapine; Polypharmacy; Random Allocation; Rats; Rats, Sprague-Dawley; Schizophrenia | 2012 |
Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Glutamic Acid; Haloperidol; Humans; Male; Mastication; Movement; Rats; Rats, Wistar; Treatment Outcome | 2012 |
Enhanced reward-facilitating effects of d-amphetamine in rats in the quinpirole model of obsessive-compulsive disorder.
Topics: Analysis of Variance; Animals; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphetamine; Disease Models, Animal; Dopamine Antagonists; Electric Stimulation; Haloperidol; Male; Obsessive-Compulsive Disorder; Quinpirole; Rats; Rats, Wistar; Reward; Self Administration | 2013 |
Aquaporin-4 knockout abolishes apomorphine-induced tardive dyskinesia following chronic treatment with neuroleptics.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Aquaporin 4; Clozapine; Corpus Striatum; Disease Models, Animal; Glial Fibrillary Acidic Protein; Haloperidol; Hippocampus; Male; Mastication; Mice; Mice, Knockout; Motor Activity; Movement Disorders | 2012 |
Intra-orbitofrontal cortex injection of haloperidol removes the beneficial effect of methylphenidate on reversal learning of spontaneously hypertensive rats in an attentional set-shifting task.
Topics: Animals; Attention; Attention Deficit and Disruptive Behavior Disorders; Disease Models, Animal; Dopaminergic Neurons; Drug Interactions; Frontal Lobe; Haloperidol; Male; Methylphenidate; Microinjections; Rats; Rats, Inbred SHR; Rats, Wistar; Reversal Learning; Set, Psychology | 2013 |
Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Exploratory Behavior; Haloperidol; Lameness, Animal; Locomotion; Male; Physical Conditioning, Animal; Rats; Rats, Wistar | 2013 |
Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.
Topics: Animals; Behavior, Animal; Clomipramine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Fluvoxamine; GABA Modulators; Haloperidol; Male; Mastication; Mianserin; Obsessive-Compulsive Disorder; Piperazines; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2013 |
Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration.
Topics: Animals; Behavior, Animal; Benzazepines; Decision Making; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Gambling; Haloperidol; Male; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2013 |
Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Excitatory Amino Acid Transporter 3; Female; Gene Expression Regulation; Glutamate Plasma Membrane Transport Proteins; Glutamic Acid; Haloperidol; Hippocampus; Humans; Male; Rats; Rats, Sprague-Dawley; Schizophrenia; Temporal Lobe; Vesicular Glutamate Transport Protein 1; Vesicular Glutamate Transport Protein 2; Vesicular Glutamate Transport Proteins | 2013 |
Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.
Topics: Administration, Oral; Age Factors; Animals; Animals, Newborn; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Dopamine Antagonists; Electric Stimulation; Electrodes, Implanted; Haloperidol; Hippocampus; Ibotenic Acid; Limbic System; Male; Membrane Potentials; Microinjections; Neurons; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Schizophrenia | 2002 |
Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism.
Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Auditory Perceptual Disorders; Bungarotoxins; Clozapine; Dihydro-beta-Erythroidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electroencephalography; Evoked Potentials, Auditory; Haloperidol; Hippocampus; Male; Mice; Mice, Inbred DBA; Nicotinic Antagonists; Receptors, Nicotinic; Time Factors | 2003 |
Effect of Emblica officinalis tannoids on a rat model of tardive dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Antioxidants; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Euphorbiaceae; GABA Modulators; Haloperidol; Male; Phytotherapy; Plant Extracts; Plant Roots; Rats; Rats, Wistar; Tannins; Valproic Acid; Vitamin E | 2000 |
Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Haloperidol; Male; Microinjections; Oxidopamine; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |
Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Conditioning, Psychological; Disease Models, Animal; Dizocilpine Maleate; Drinking Behavior; Haloperidol; Inhibition, Psychological; Male; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Schizophrenic Psychology | 2003 |
Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Topics: Administration, Oral; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Injections; Male; Mastication; MSH Release-Inhibiting Hormone; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Motor Activity; Random Allocation; Reserpine; Risperidone | 2003 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Fibrosarcoma; Haloperidol; Hand Strength; Humerus; Hyperalgesia; Male; Mice; Mice, Inbred C3H; Morpholines; Myositis; Naphthalenes; Neoplasm Transplantation; Neoplasms; Pain; Piperidines; Psychomotor Performance; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Eating; Female; Food Preferences; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Sex Characteristics; Weight Gain | 2003 |
The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.
Topics: Animals; Ataxia; Behavior, Animal; Catalepsy; Diamines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Antagonists; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Haloperidol; Kainic Acid; Memantine; Mice; Mice, Inbred Strains; N-Methylaspartate; Quaternary Ammonium Compounds; Seizures; Structure-Activity Relationship; Time Factors | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Catalepsy; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Haloperidol; Hippocampus; Homovanillic Acid; Hypothalamus; Locus Coeruleus; Male; Medial Forebrain Bundle; Nerve Degeneration; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Reaction Time; Serotonin; Substantia Nigra; Thalamus; Tyrosine | 2003 |
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Cebus; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Excitatory Amino Acid Antagonists; Female; Haloperidol; Neural Inhibition; Phencyclidine; Reflex, Startle; Schizophrenia | 2003 |
Tail-swing behavior: a novel animal model for anxiety.
Topics: Animals; Anxiety; Behavior, Animal; Desipramine; Diazepam; Disease Models, Animal; Haloperidol; Immobilization; Male; Mice; Muscle Tonus; Muscle, Skeletal; Nitrazepam; Psychotropic Drugs; Tail | 2003 |
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia.
Topics: Aging; Amphetamine; Animals; Central Nervous System Stimulants; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Female; GABA Antagonists; Haloperidol; Hippocampus; In Vitro Techniques; Inhibition, Psychological; Interferon Inducers; Male; Motor Activity; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia | 2003 |
Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Comorbidity; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley | 2003 |
Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action.
Topics: Animals; Antipsychotic Agents; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Lipid Peroxidation; Male; Oxidative Stress; Phytotherapy; Plant Extracts; Plant Roots; Rats; Rats, Wistar; Superoxide Dismutase; Withania | 2003 |
Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Glutathione; Haloperidol; Lipid Peroxidation; Male; Neuroprotective Agents; Rats; Rats, Wistar; Superoxide Dismutase; Tacrolimus | 2003 |
Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Mastication; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Time; Time Factors | 2003 |
The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Drug Administration Routes; Drug Interactions; Enkephalins; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Haloperidol; In Situ Hybridization; Male; Parkinson Disease; Protein Precursors; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; RNA, Messenger | 2003 |
Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cell Survival; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Immunohistochemistry; Male; Microscopy, Electron; Nerve Degeneration; Presynaptic Terminals; Prosencephalon; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Salicylamides; Synaptic Transmission; Tyrosine 3-Monooxygenase | 2004 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Depression; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Haloperidol; Mice; Mice, Knockout; Motor Activity; Neurotransmitter Agents; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles | 2003 |
The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Inhibition, Psychological; Jaw; Male; Motor Activity; Movement; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tremor; Xanthines | 2004 |
[Altered behavioral response to centrally acting drugs in mice lacking PACAP].
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Fluoxetine; Haloperidol; Mice; Mice, Knockout; Neuropeptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Risperidone | 2003 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Rats; Rats, Sprague-Dawley; Risperidone; Stereotyped Behavior; Time Factors | 2004 |
Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Gait Disorders, Neurologic; Haloperidol; Inhibition, Psychological; Male; Neurotensin; Rats; Rats, Brattleboro; Rats, Long-Evans; Reflex, Startle; Schizophrenia; Species Specificity | 2004 |
Motor disturbances in mice with deficiency of the sodium channel gene Scn8a show features of human dystonia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Biperiden; Brain; Diazepam; Disease Models, Animal; Dystonia; Electroencephalography; Haloperidol; Humans; Immunohistochemistry; Mice; Mice, Mutant Strains; Motor Activity; Muscarinic Antagonists; Muscle, Skeletal; NAV1.6 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Phenytoin; Sodium Channels; Tyrosine 3-Monooxygenase | 2003 |
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Cycloserine; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycine; Haloperidol; Mastication; Rats; Rats, Sprague-Dawley | 2004 |
Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Electrochemistry; Epilepsy, Temporal Lobe; Haloperidol; In Vitro Techniques; Kainic Acid; Male; Methamphetamine; Microdialysis; Motor Activity; Psychotic Disorders; Rats; Rats, Sprague-Dawley | 2004 |
Glutamatergic regulation of long-term grafts of fetal lateral ganglionic eminence in a rat model of Huntington's disease.
Topics: Animals; Brain Injuries; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Fetal Tissue Transplantation; Fluorescent Antibody Technique; Glutamine; Haloperidol; Huntington Disease; Immunohistochemistry; Male; Neurons, Afferent; Proto-Oncogene Proteins c-fos; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2004 |
Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression.
Topics: Animals; Antipsychotic Agents; Binding Sites; Clozapine; Disease Models, Animal; Drug Administration Schedule; Glutamate Decarboxylase; Haloperidol; Isoenzymes; Limbic System; Male; Parietal Lobe; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; RNA, Complementary; Schizophrenia; Temporal Lobe; Up-Regulation | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Chlorpromazine; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Haloperidol; Hyperkinesis; Injections, Intraperitoneal; Male; Methamphetamine; Mice; Piperazines; Pyridines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2004 |
Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia.
Topics: Animals; Antioxidants; Cabergoline; Cell Death; Cell Hypoxia; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ergolines; Free Radical Scavengers; Free Radicals; Gene Expression; Genes, bcl-2; Glucose; Haloperidol; Humans; Ischemia; Neurons; Thiobarbituric Acid Reactive Substances; Time Factors; Tretinoin; Vitamin E | 2004 |
Atypical antipsychotic profile of flunarizine in animal models.
Topics: Administration, Oral; Animals; Catalepsy; Dextroamphetamine; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Flunarizine; Haloperidol; Mice; Motor Activity; Receptors, N-Methyl-D-Aspartate; Time Factors | 2005 |
Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzoates; Biphenyl Compounds; Disease Models, Animal; DNA-Binding Proteins; Docosahexaenoic Acids; Dyskinesia, Drug-Induced; Gene Expression Regulation; Genetic Predisposition to Disease; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Nuclear Receptor Subfamily 4, Group A, Member 1; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Retinoid X Receptors; Transcription Factors | 2004 |
Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding Sites; Corpus Striatum; Cyclic N-Oxides; Disease Models, Animal; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Electron Spin Resonance Spectroscopy; Haloperidol; Humans; Male; Mastication; Motor Activity; Movement Disorders; Neuroprotective Agents; Nitrogen Oxides; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, Dopamine D2 | 2004 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervation; Disease Models, Animal; Gait Disorders, Neurologic; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereoisomerism | 2005 |
Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.
Topics: Aging; Animals; Disease Models, Animal; Epithelial Cells; Haloperidol; Hyperprolactinemia; Male; Proliferating Cell Nuclear Antigen; Prostate; Rats | 2004 |
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Glutamic Acid; Haloperidol; Male; Mastication; Rats; Rats, Wistar; Reserpine; Synaptosomes; Tongue | 2005 |
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Dopamine Antagonists; Drug Administration Routes; Dyskinesia, Drug-Induced; Haloperidol; Infusion Pumps; Male; Mastication; Olanzapine; Raclopride; Radioligand Assay; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Selective Serotonin Reuptake Inhibitors; Time Factors; Tritium | 2005 |
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
Topics: Adaptor Proteins, Vesicular Transport; Aged; Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Female; Haloperidol; Hippocampus; Humans; Immunohistochemistry; Ketamine; Male; Maze Learning; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Vesicular Glutamate Transport Protein 1; Vesicular Inhibitory Amino Acid Transport Proteins | 2005 |
A putative animal model of the "prodromal" state of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzazepines; Central Nervous System Stimulants; Clozapine; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Haloperidol; Inhibition, Psychological; Male; Motor Activity; Neural Inhibition; Random Allocation; Rats; Rats, Sprague-Dawley; Reaction Time; Reflex, Startle; Schizophrenia; Substance Withdrawal Syndrome; Time Factors | 2005 |
Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.
Topics: alpha-Tocopherol; Animals; Ascorbic Acid; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Enzyme Inhibitors; Haloperidol; Indazoles; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitroarginine; Time Factors; Vitamins | 2005 |
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Clozapine; Dextroamphetamine; Dioxanes; Discrimination, Psychological; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Imipramine; Injections, Intraperitoneal; Male; Phencyclidine; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Recognition, Psychology; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Social Behavior; Tacrine; Tropanes | 2005 |
Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Oxidopamine; Parkinson Disease, Secondary; Potassium Channels; Rats; Rats, Sprague-Dawley | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol.
Topics: Amygdala; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Drinking Behavior; Haloperidol; Male; Nerve Net; Neural Inhibition; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2006 |
Cortical gene expression in the neonatal ventral-hippocampal lesion rat model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Disease Models, Animal; Doublecortin Protein; Frontal Lobe; Gene Expression Regulation; Haloperidol; Hippocampus; Male; Oligonucleotide Array Sequence Analysis; Rats; Rats, Inbred F344; Rats, Inbred Lew; RNA, Messenger; Schizophrenia; Temporal Lobe | 2005 |
Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Bupropion; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Evoked Potentials, Auditory; Haloperidol; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Receptors, Nicotinic; Schizophrenia | 2005 |
MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electromyography; Haloperidol; Male; Movement; Muscle, Skeletal; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles; Time Factors | 2005 |
Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity in the rat.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Electric Stimulation; Haloperidol; Hypokinesia; Male; Motor Activity; Motor Cortex; Neurons; Rats; Rats, Wistar; Spinal Cord | 2005 |
Novel oral drug administration in an animal model of neuroleptic therapy.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Clozapine; Diazepam; Disease Models, Animal; Dyskinesia, Drug-Induced; Grooming; Haloperidol; Male; Mastication; Motivation; Motor Activity; Rats; Rats, Sprague-Dawley; Reaction Time | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; Electrocardiography; Guinea Pigs; Haloperidol; Heart; Humans; Injections, Intravenous; Long QT Syndrome; Male; Nifedipine; Pimozide; Piperidines; Pyridines; Quinidine; Reproducibility of Results; Telemetry; Terfenadine; Thioridazine | 2005 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Indoles; Isoindoles; Male; Mice; Mice, Inbred ICR; Motor Activity; Obsessive-Compulsive Disorder; Piperazines; Receptor, Serotonin, 5-HT1A; Risperidone; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 2005 |
The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drinking Behavior; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Jaw; Male; Motor Activity; Movement; Organic Chemicals; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2006 |
A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Diazepam; Disease Models, Animal; Dopamine; Electrophysiology; GABA Modulators; Gene Targeting; Haloperidol; Immunohistochemistry; Ion Channel Gating; Mice; Mice, Knockout; Motor Activity; Protein Subunits; Receptors, GABA-A; Schizophrenia | 2005 |
Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Disease Models, Animal; Female; Fluoxetine; Haloperidol; Male; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Time Factors | 2005 |
Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Buspirone; Chlordiazepoxide; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Haloperidol; Male; Models, Neurological; Motor Activity; Phobic Disorders; Piperazines; Rats; Rats, Wistar; Reproducibility of Results; Serotonin Receptor Agonists; Stress, Psychological | 2006 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Haloperidol; Lipid Peroxidation; Male; Membrane Lipids; Olanzapine; Rats; Rats, Wistar; Risperidone; Schizophrenia; Superoxide Dismutase | 2007 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Functional Laterality; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Thiazoles; Time Factors | 2006 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Exploratory Behavior; Haloperidol; Infusion Pumps, Implantable; Male; Motor Activity; Phenotype; Rats; Rats, Sprague-Dawley; Risperidone | 2006 |
Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Exploratory Behavior; Female; Haloperidol; Motor Activity; Neural Inhibition; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Vitamin D Deficiency | 2006 |
Linking animal models of psychosis to computational models of dopamine function.
Topics: Action Potentials; Amphetamine; Animals; Computer Simulation; Conditioning, Classical; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Learning Disabilities; Models, Biological; Neurons; Predictive Value of Tests; Psychotic Disorders | 2007 |
Targeting pain-suppressed behaviors in preclinical assays of pain and analgesia: effects of morphine on acetic acid-suppressed feeding in C57BL/6J mice.
Topics: Acetic Acid; Analgesics, Opioid; Animals; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Drug Evaluation, Preclinical; Drug Interactions; Feeding Behavior; Haloperidol; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Morphine; Narcotic Antagonists; Pain; Pain Measurement; Predictive Value of Tests; Receptors, Opioid, mu; Time Factors | 2006 |
Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.
Topics: Acoustic Stimulation; Amphetamine; Animals; Auditory Threshold; Brain Stem; Central Nervous System Stimulants; Cerebral Cortex; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Electroencephalography; Evoked Potentials, Auditory; Female; GTP-Binding Protein alpha Subunits, Gs; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Schizophrenia | 2006 |
Effects of diphenyl-diselenide on orofacial dyskinesia model in rats.
Topics: Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Organoselenium Compounds; Rats; Rats, Wistar | 2006 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Haloperidol; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Weight Gain | 2006 |
Efficacy of olanzapine and haloperidol in an animal model of mania.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Bipolar Disorder; Disease Models, Animal; Drug Evaluation; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Haloperidol; Male; Olanzapine; Ouabain; Rats; Rats, Sprague-Dawley | 2006 |
Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid.
Topics: Animals; Brain; Catalepsy; Cell Line, Transformed; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Haloperidol; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred C57BL; Molecular Structure; Motor Activity; Neurons; Phosphorylation; Propionates; Receptors, Dopamine D2 | 2006 |
Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Topics: Adenosine; Akathisia, Drug-Induced; Animals; Antioxidants; Behavior, Animal; Brain; Caffeine; Catalase; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Haloperidol; Lipid Peroxidation; Male; Mastication; Maze Learning; Motor Activity; Neurotransmitter Agents; Rats; Rats, Wistar; Receptors, Purinergic P1; Stereotyped Behavior; Superoxide Dismutase; Vasodilator Agents | 2006 |
Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Drug Combinations; Excitatory Amino Acid Antagonists; Haloperidol; Male; Proteome; Rats; Rats, Sprague-Dawley; Schizophrenia; Serotonin Antagonists; Thalamus | 2007 |
Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Eating; Hallucinogens; Haloperidol; Male; Phencyclidine; Rats; Rats, Sprague-Dawley; Reward; Schizophrenia; Sucrose | 2007 |
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system.
Topics: Animals; Antibodies, Anti-Idiotypic; Antidepressive Agents, Second-Generation; Autoimmunity; Brain; Cognition; Depression; Disease Models, Animal; Female; Fluoxetine; Haloperidol; Limbic System; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C3H; Motor Activity; Physical Exertion; Ribosomal Proteins; Rotarod Performance Test | 2007 |
Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia.
Topics: Animals; Brain Diseases, Metabolic; Cognition Disorders; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Haloperidol; Hippocampus; Long-Term Potentiation; Male; Maze Learning; Memory Disorders; Methylphenidate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Neurocognitive Disorders; Schizophrenia | 2007 |
Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Haloperidol; Interferon-gamma; Interleukin-1beta; Interleukin-6; Mice; Microglia; Nitric Oxide; Risperidone; Schizophrenia; Tumor Necrosis Factor-alpha | 2007 |
Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Imidazoles; Indoles; Male; Maze Learning; Phencyclidine; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenic Psychology | 2007 |
Lack of effect of dopaminergic antagonists in a rodent model of peritoneal sepsis.
Topics: Animals; Biomarkers; Clozapine; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Inflammation; Intestinal Perforation; Male; Neutrophil Infiltration; Peritoneum; Rats; Rats, Wistar; Sepsis | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Hallucinogens; Haloperidol; Impulsive Behavior; Male; Olanzapine; Phencyclidine; Quetiapine Fumarate; Rats; Rats, Wistar; Reaction Time; Risperidone; Schizophrenia | 2007 |
Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrochemistry; Female; Haloperidol; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Motor Activity; Piperazines; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Agonists | 2007 |
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Arginine Vasopressin; Clozapine; Deamino Arginine Vasopressin; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Habituation, Psychophysiologic; Haloperidol; Neural Inhibition; Neurotensin; Rats; Rats, Brattleboro; Rats, Long-Evans; Rats, Mutant Strains; Reflex, Startle; Risperidone; Schizophrenia; Statistics, Nonparametric | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; Haloperidol; Hippocampus; Interneurons; Male; Neural Inhibition; Neurons; Prefrontal Cortex; Psychotic Disorders; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2007 |
Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice.
Topics: Animals; Antipsychotic Agents; Autoradiography; Baclofen; Brain; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Agonists; Haloperidol; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neural Inhibition; Receptors, GABA-B; Reflex, Startle; Schizophrenia | 2007 |
Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Psychological; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Emotions; Fear; Freezing Reaction, Cataleptic; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred C57BL; Restraint, Physical; Stress, Psychological | 2007 |
Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1.
Topics: Animals; Antipsychotic Agents; Arousal; Attention; Behavior, Animal; Disease Models, Animal; Genes, Recessive; Grooming; Haloperidol; Male; Maze Learning; Mental Recall; Mice; Mice, Knockout; Mice, Neurologic Mutants; Models, Genetic; Nesting Behavior; Phospholipase C beta; Reflex, Startle; Schizophrenia; Signal Transduction; Social Behavior | 2008 |
Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Topics: Akathisia, Drug-Induced; Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Flavonoids; Glutathione; Haloperidol; Lipid Peroxidation; Male; Mastication; Maze Learning; Motor Activity; Neuroprotective Agents; Rats; Rats, Wistar; Receptors, Dopamine; Rutin; Stereotyped Behavior | 2007 |
In hamsters dopamine D2 receptors affect ventilation during and following intermittent hypoxia.
Topics: Animals; Body Temperature; Carbon Dioxide; Carotid Body; Cricetinae; Disease Models, Animal; Domperidone; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Hypoxia; Male; Mesocricetus; Pulmonary Ventilation; Receptors, Dopamine D2; Tidal Volume; Time Factors | 2007 |
Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo.
Topics: Age Factors; Animals; Antipsychotic Agents; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Gene Expression Regulation; Haloperidol; Huntingtin Protein; Huntington Disease; Lentivirus; Mutation; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Phosphopyruvate Hydratase; Rats; Rats, Wistar | 2008 |
Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the tail suspension test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Cycloheptanes; Depressive Disorder; Disease Models, Animal; Haloperidol; Hindlimb Suspension; Immobility Response, Tonic; Male; Mice; Motor Activity | 2008 |
[Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response].
Topics: Amphetamines; Animals; Disease Models, Animal; Dopamine; Fluoxetine; Haloperidol; Homovanillic Acid; Male; Mice; Receptor, Serotonin, 5-HT1A; Tourette Syndrome | 2007 |
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Topics: Animals; Antipsychotic Agents; Brain Diseases; Control Groups; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Movement Disorders; Neuroprotective Agents; Oxidative Stress; Pregnanolone; Progesterone; Rats; Rats, Inbred ACI; Receptors, GABA-A | 2008 |
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Haloperidol; Matched-Pair Analysis; Phencyclidine; Piperazines; Rats; Rats, Inbred Strains; Schizophrenia; Schizophrenic Psychology; Social Behavior; Social Behavior Disorders; Thiazoles | 2008 |
Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Binding Sites; Brain; Diazepam; Disease Models, Animal; Drug Combinations; Flumazenil; Haloperidol; Hippocampus; Humans; Injections, Intraperitoneal; Muscimol; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Schizophrenia; Thalamus; Tissue Distribution | 2008 |
Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia.
Topics: Animals; Attention; Clozapine; Cognition; Cognition Disorders; Disease Models, Animal; Haloperidol; Male; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Schizophrenia; Treatment Outcome | 2008 |
The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Conditioning, Psychological; Disease Models, Animal; Electroshock; Female; Haloperidol; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neural Inhibition; Reflex, Startle; Risperidone; Schizophrenia | 2008 |
U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Male; Movement Disorders; Pregnatrienes; Rats; Rats, Wistar | 2007 |
Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Receptor Agonists | 2007 |
Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Morpholines; Motivation; Motor Activity; Rats; Rats, Wistar; Reboxetine; Reward; Stress, Psychological | 2008 |
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Fenclonine; Haloperidol; Hypokinesia; Isoindoles; Male; Mice; Motor Activity; Muscarinic Antagonists; Piperazines; Pyrimidines; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Trihexyphenidyl | 2008 |
Gamma-aminobutyric acid and basal ganglia outflow pathways.
Topics: Animals; Basal Ganglia; Catalepsy; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Humans; Locomotion; Muscimol; Neural Pathways; Posture; Rats; Stereotyped Behavior; Synaptic Transmission | 1984 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Mouth Diseases; Movement Disorders; Occipital Lobe; Rats; Substance Withdrawal Syndrome | 1980 |
Neuroleptic-induced acute dyskinesias in rhesus monkeys.
Topics: Acute Disease; Animals; Antipsychotic Agents; Benzamides; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Macaca mulatta; Scopolamine | 1981 |
Animal models of tardive dyskinesias.
Topics: Animals; Antipsychotic Agents; Apomorphine; Chlorpromazine; Disease Models, Animal; Dyskinesia, Drug-Induced; Epidemiologic Methods; Guinea Pigs; Haloperidol; Humans; Time Factors | 1983 |
Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Glutamate Decarboxylase; Haloperidol; Humans; Male; Motor Activity; Neurotransmitter Agents; Norepinephrine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 1983 |
[Effect of central effective substances on alcohol preference].
Topics: Alcohol Drinking; Alcoholism; Animals; Arecoline; Atropine; Central Nervous System Stimulants; Cyproheptadine; Disease Models, Animal; Drinking Behavior; Food Preferences; Haloperidol; Humans; Isoproterenol; Male; Methamphetamine; Mice; Phenoxybenzamine; Picrotoxin; Propranolol | 1983 |
Parkinson's disease: studies with an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology; Haloperidol; Haplorhini; Hydroxydopamines; Mice; Oxidopamine; Parkinson Disease; Rats; Tyrosine 3-Monooxygenase | 1984 |
Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Humans; Indoles; Male; Molindone; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone; Stereotyped Behavior | 1984 |
Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics.
Topics: Adrenal Medulla; Animals; Disease Models, Animal; Flupenthixol; Haloperidol; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Rotation | 1984 |
Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans.
Topics: Aging; Animals; Apomorphine; Brain Chemistry; Disease Models, Animal; Dopamine; Dystonia Musculorum Deformans; Haloperidol; Motor Activity; Mutation; Norepinephrine; Pedigree; Rats; Rats, Mutant Strains | 1984 |
[Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)].
Topics: Adult; Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Drug Tolerance; Haloperidol; Humans; Male; Mice; Receptors, Dopamine; Schizophrenia, Paranoid; Spiperone; Trifluoperazine | 1984 |
Norepinephrine-induced pulmonary petechiae in the rat: an experimental model with potential implications for sudden infant death syndrome.
Topics: Animals; Blood Pressure; Catecholamines; Disease Models, Animal; Haloperidol; Humans; Lung Diseases; Male; Norepinephrine; Phentolamine; Purpura; Rats; Sudden Infant Death; Timolol | 1984 |
[The effects of chronic methamphetamine and single haloperidol injections on thiamine and its phosphate ester levels in the rat brain].
Topics: Animals; Brain; Disease Models, Animal; Haloperidol; Humans; Male; Methamphetamine; Rats; Rats, Inbred Strains; Schizophrenia; Thiamine; Thiamine Monophosphate; Thiamine Pyrophosphate; Thiamine Triphosphate; Time Factors | 1984 |
Oral tardive dyskinesia in the rat.
Topics: Animals; Apomorphine; Bruxism; Dental Occlusion, Traumatic; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Time Factors | 1983 |
LSD-potentiated apomorphine hypermotility: a model for differentiating antipsychotic drugs.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Disease Models, Animal; Drug Antagonism; Haloperidol; Humans; Hyperkinesis; Lysergic Acid Diethylamide; Male; Motor Activity; Rats; Rats, Inbred Strains; Sulpiride | 1983 |
Response to intracerebral dopamine injection as a model of schizophrenic symptomatology.
Topics: Animals; Brain Mapping; Corpus Striatum; Disease Models, Animal; Dopamine; Grooming; Haloperidol; Humans; Macaca fascicularis; Nucleus Accumbens; Schizophrenia | 1983 |
Haloperidol-induced hyperactivity in neonatal rats: effect of lithium and stimulants.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Humans; Hyperkinesis; Lithium; Lithium Carbonate; Male; Methylphenidate; Motor Activity; Rats; Rats, Inbred Strains | 1982 |
MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
Topics: Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Thiazolidines; Thyrotropin-Releasing Hormone | 1982 |
Experimental tardive dyskinesia.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Macaca fascicularis; Macaca mulatta; Mesencephalon; Neural Pathways | 1982 |
Galloping induced by pontine tegmentum damage in rats: a form of "Parkinsonian festination" not blocked by haloperidol.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Locomotion; Male; Motor Activity; Parkinson Disease; Pons; Rats | 1981 |
A new animal model for Tourette syndrome.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Haloperidol; Humans; Male; Nitriles; Rats; Rats, Inbred Strains; Rodent Diseases; Stereotyped Behavior; Tourette Syndrome | 1982 |
Hormonal interference in experimental models of depression.
Topics: Animals; Apomorphine; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Haloperidol; Humans; Motor Activity; Muscle Tonus; Prolactin; Receptors, Dopamine | 1982 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Contraction; Muscle Rigidity; Muscle Tonus; Neurophysiology; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Reflex, Stretch; Reserpine | 1982 |
Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.
Topics: Animals; Baclofen; Brain Chemistry; Disease Models, Animal; Dopamine; Drug Interactions; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Rats; Rats, Inbred Strains | 1982 |
Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Estradiol; Female; Haloperidol; Humans; Rats; Receptors, Dopamine; Stereotyped Behavior; Substance Withdrawal Syndrome | 1981 |
Further analysis of the specificity of a novel animal model of depression--effects of an antihistaminic, antipsychotic and anxiolytic compound.
Topics: Animals; Corticosterone; Depressive Disorder; Disease Models, Animal; Exploratory Behavior; Haloperidol; Humans; Male; Motivation; Motor Activity; Oxazepam; Rats; Rats, Inbred Strains; Stress, Physiological; Tripelennamine | 1982 |
Animal models of tardive dyskinesia [proceedings].
Topics: Animals; Cebidae; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans; Rats | 1981 |
The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Mastication; Motor Activity; Rats; Rats, Sprague-Dawley; Videotape Recording | 1995 |
Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine.
Topics: Animals; Diphenhydramine; Disease Models, Animal; Dose-Response Relationship, Drug; Dystonia; Haloperidol; Histamine; Male; Movement Disorders; Rats; Rats, Sprague-Dawley; Time Factors; Torticollis | 1995 |
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 1995 |
Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment.
Topics: Animals; Brain Mapping; Disease Models, Animal; Haloperidol; Hippocampus; Limbic System; Male; Neural Inhibition; Neural Pathways; Nucleus Accumbens; Rats; Rats, Inbred Strains; Reaction Time; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Schizophrenic Psychology | 1995 |
Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats.
Topics: Analysis of Variance; Anesthesia; Animals; Disease Models, Animal; Dopamine; Haloperidol; Male; Microelectrodes; Neurons; Rats; Rats, Sprague-Dawley; Schizophrenia; Substantia Nigra | 1994 |
Amphetamine and haloperidol modulatory effects on Purkinje cell activity and on EEG power spectra in the acute rat model of epilepsy.
Topics: Amphetamine; Animals; Disease Models, Animal; Electroencephalography; Epilepsy; Haloperidol; Male; Purkinje Cells; Rats; Rats, Wistar; Seizures | 1994 |
[The role of lipid peroxidation in the pathogenesis of neuropathological syndromes and in experimental therapy].
Topics: Animals; Antioxidants; Bemegride; Brain Chemistry; Chorea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Epilepsy; Female; GABA Agonists; Haloperidol; Hyperkinesis; Lipid Peroxidation; Male; Mice; Picrotoxin; Rats; Syndrome | 1994 |
Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Mastication; Nipecotic Acids; Rats; Rats, Sprague-Dawley; Single-Blind Method; Tiagabine | 1994 |
The relationship between motor effects in rats following acute and chronic haloperidol treatment.
Topics: Acute Disease; Animals; Catalepsy; Chronic Disease; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Motor Activity; Mouth; Movement; Rats; Rats, Sprague-Dawley | 1994 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol; Haloperidol; Male; Mice; Oxotremorine; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1994 |
Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations.
Topics: Animals; Behavior, Animal; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Motor Activity; Rats; Receptors, Presynaptic; Stereotyped Behavior; Substance-Related Disorders | 1993 |
Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder.
Topics: Animals; Clomipramine; Conditioning, Operant; Desipramine; Diazepam; Disease Models, Animal; Drinking Behavior; Fluoxetine; Haloperidol; Male; Obsessive-Compulsive Disorder; Rats; Rats, Wistar; Reinforcement Schedule; Selective Serotonin Reuptake Inhibitors | 1993 |
Chronic haloperidol: neural correlates of motor disorders in an invertebrate model.
Topics: Animals; Catecholamines; Disease Models, Animal; Dopamine; Fluorescence; Glyoxylates; Haloperidol; Histocytochemistry; Leeches; Levodopa; Locomotion; Movement; Movement Disorders; Neurotransmitter Agents | 1994 |
[Intracerebral-ventricular injection of 4-aminopyridine induced convulsion in rabbits].
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Disease Models, Animal; Female; Haloperidol; Injections, Intraventricular; Male; Phentolamine; Rabbits; Scopolamine; Seizures | 1993 |
Differential effects of amphetamine and haloperidol on recovery after global forebrain ischemia.
Topics: Animals; Brain Ischemia; Dextroamphetamine; Disease Models, Animal; Gerbillinae; Haloperidol; Male; Memory; Motor Activity; Prosencephalon; Spatial Behavior | 1994 |
Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzothiazoles; Cebus; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Female; Haloperidol; Lisuride; Male; Piperidines; Pramipexole; Quinpirole; Raclopride; Salicylamides; Thiazoles | 1993 |
[Role of the dopaminergic system in experimental models of epilepsy].
Topics: Amygdala; Animals; Benzazepines; Cerebral Cortex; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electric Stimulation; Electroencephalography; Epilepsy; Haloperidol; Hippocampus; Male; Rabbits; Receptors, Dopamine | 1993 |
The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol.
Topics: Animals; Clozapine; Cricetinae; Disease Models, Animal; Dystonia; Female; Haloperidol; Male; Mesocricetus; Mutation | 1993 |
[Epiphyseal interrelations with the striatum in the haloperidol-induced catalepsy model].
Topics: Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Haloperidol; Male; Pineal Gland; Rats; Time Factors | 1993 |
Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Electric Stimulation; Electroencephalography; Habituation, Psychophysiologic; Haloperidol; Limbic System; Male; Models, Neurological; Motor Activity; Raclopride; Rats; Rats, Wistar; Receptors, Dopamine D1; Salicylamides; Schizophrenia; Seizures; Stereotyped Behavior; Tegmentum Mesencephali; Time Factors | 1993 |
Acute blockade of dopamine receptors with haloperidol: a retinal model to study impairments of dopaminergic transmission.
Topics: Animals; Chickens; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electrooculography; Haloperidol; Injections; Light; Membrane Potentials; Retina; Synaptic Transmission; Vitreous Body | 1993 |
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Hippocampus; Ibotenic Acid; Motor Activity; Pregnancy; Rats; Rats, Sprague-Dawley; Schizophrenia; Stress, Psychological; Swimming | 1993 |
Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia.
Topics: Animals; Apomorphine; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Habituation, Psychophysiologic; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenic Psychology | 1993 |
Role of dopamine D-1 and D-2 antagonists in a model of focal epilepsy induced by electrical stimulation of hippocampus and amygdala in the rabbit.
Topics: Amygdala; Animals; Benzazepines; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Electric Stimulation; Electroencephalography; Epilepsies, Partial; Haloperidol; Hippocampus; Male; Rabbits; Receptors, Dopamine D1 | 1995 |
Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity.
Topics: Animals; Disease Models, Animal; Electromyography; Haloperidol; Joints; Male; Muscle Spasticity; Muscle, Skeletal; Parkinson Disease; Rats; Rats, Wistar; Tibia; Time Factors | 1996 |
PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats.
Topics: Animals; Cerebral Infarction; Disease Models, Animal; Haloperidol; Infusions, Intravenous; Ischemic Attack, Transient; Male; Neuroprotective Agents; Rats; Receptors, sigma; Time Factors; Treatment Outcome | 1996 |
Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level.
Topics: Animals; Antipsychotic Agents; Atropine; Body Temperature Regulation; Cholinergic Antagonists; Creatine Kinase; Dantrolene; Disease Models, Animal; Dopamine Antagonists; Electromyography; Haloperidol; Hot Temperature; Male; Muscle Relaxants, Central; Muscle Rigidity; Neuroleptic Malignant Syndrome; Rabbits | 1996 |
SA4503, a novel cognitive enhancer with sigma1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice.
Topics: Amnesia; Analysis of Variance; Animals; Avoidance Learning; Cognition; Disease Models, Animal; Dizocilpine Maleate; Dopamine Antagonists; Drug Interactions; Excitatory Amino Acid Antagonists; Haloperidol; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Maze Learning; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Piperazines; Progesterone; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Spatial Behavior | 1997 |
[Zotepin--its value and potentials for further development].
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiepins; Disease Models, Animal; Haloperidol; Humans; Rats; Schizophrenia | 1994 |
Prefrontal cortical and hippocampal modulation of dopamine-mediated effects.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Apomorphine; Disease Models, Animal; Dopamine; Haloperidol; Hippocampus; Humans; Motor Activity; Prefrontal Cortex; Rats; Reflex, Startle; Schizophrenia; Sexual Maturation; Stereotyped Behavior; Stress, Psychological; Synapses; Synaptic Transmission | 1998 |
Dopaminergic modulation of lithium/pilocarpine-induced status epilepticus in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Azepines; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Lipid Peroxidation; Lithium; Male; Muscarinic Agonists; Pilocarpine; Rats; Rats, Wistar; Status Epilepticus; Sulpiride | 1997 |
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide Synthase; Nitroarginine; Parkinson Disease; Rats; Rats, Wistar; Vasodilator Agents | 1997 |
Kainic acid lesions in adult rats as a model of schizophrenia: changes in auditory information processing.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Auditory Perception; Disease Models, Animal; Electrodes, Implanted; Electrophysiology; Evoked Potentials; Excitatory Amino Acid Agonists; Haloperidol; Hippocampus; Injections, Intraventricular; Kainic Acid; Male; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Schizophrenic Psychology | 1998 |
A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dextroamphetamine; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Hallucinogens; Haloperidol; Male; Motor Activity; Phencyclidine; Predictive Value of Tests; Rats; Rats, Wistar; Schizophrenia; Social Behavior; Stereotyped Behavior | 1998 |
Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Dextroamphetamine; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Drug Administration Schedule; Haloperidol; Limbic System; Male; Motor Activity; Phencyclidine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Schizophrenia; Stress, Psychological; Time Factors | 1998 |
Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Rats; Rats, Sprague-Dawley | 1998 |
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Scopolamine; Time Factors; Tongue; Trihexyphenidyl | 1998 |
Effects of dopaminergic drugs, occlusal disharmonies, and chronic stress on non-functional masticatory activity in the rat, assessed by incisal attrition.
Topics: Analysis of Variance; Animals; Apomorphine; Bruxism; Cocaine; Dental Occlusion, Traumatic; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Incisor; Male; Masticatory Muscles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Stress, Physiological; Tooth Attrition | 1998 |
Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Infusions, Parenteral; Male; Rats; Rats, Sprague-Dawley | 1998 |
Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Electroencephalography; Electromyography; Excitatory Amino Acid Antagonists; Hallucinogens; Haloperidol; Male; Motor Activity; Phencyclidine; Rats; Rats, Sprague-Dawley; Schizophrenia; Sleep, REM | 1998 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory Amino Acid Antagonists; Haloperidol; Kynurenic Acid; Parkinson Disease; Quinolones; Rats; Receptors, N-Methyl-D-Aspartate; Reserpine | 1998 |
The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Fasciculation; Female; Gene Expression Regulation; Haloperidol; Humans; Motor Activity; Mouth; Neurons; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription, Genetic; Videotape Recording | 1999 |
Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Nortropanes; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Risperidone; Schizophrenia | 1999 |
Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; GABA Antagonists; GABA-A Receptor Antagonists; Haloperidol; Male; Picrotoxin; Prefrontal Cortex; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia | 1999 |
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.
Topics: Animals; Antipsychotic Agents; Antisocial Personality Disorder; Behavior, Animal; Calcium Signaling; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Haloperidol; Male; Mice; Mice, Knockout; Motor Activity; Phencyclidine; Receptors, N-Methyl-D-Aspartate; Schizophrenic Psychology; Serotonin Antagonists; Sexual Behavior, Animal; Social Behavior; Stereotyped Behavior | 1999 |
Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzazepines; Catalepsy; Conditioning, Psychological; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Locomotion; Male; Metoclopramide; Mice; Mice, Inbred Strains; Time Factors | 1999 |
Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Excitatory Amino Acid Antagonists; Haloperidol; Hippocampus; Infusions, Parenteral; Male; N-Methylaspartate; Rats; Rats, Wistar; Reflex, Startle | 1999 |
Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Kava; Male; Plant Extracts; Plant Roots; Plants, Medicinal; Rats; Rats, Sprague-Dawley | 1999 |
Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Clozapine; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Jaw; Male; Mastication; Quinpirole; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Serotonin Antagonists | 1999 |
Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats.
Topics: Animals; Biomechanical Phenomena; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Female; Gonadal Steroid Hormones; Haloperidol; Head-Down Tilt; Male; Parkinson Disease; Posture; Rats; Rats, Inbred Strains; Sex Characteristics | 2000 |
Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats.
Topics: Amygdala; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Antagonists; Excitatory Amino Acid Antagonists; GABA Antagonists; Haloperidol; Male; Neural Inhibition; Picrotoxin; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Schizophrenia | 2000 |
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.
Topics: Animals; Antidepressive Agents; Apomorphine; Carbamazepine; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Male; Neurotransmitter Agents; Oxcarbazepine; Rats; Rats, Wistar; Receptors, Dopamine; Stereotypic Movement Disorder; Swimming | 2000 |
Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Injections, Intraperitoneal; Male; Methamphetamine; Piperazines; Pyrrolidines; Rats; Rats, Wistar; Receptors, sigma; Schizophrenia; Sigma-1 Receptor; Stereotyped Behavior; Tartrates | 2000 |
Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dendrites; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Microscopy, Electron; Neurons; Nucleus Accumbens; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Synapses | 2000 |
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Disease Models, Animal; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Schizophrenia; Serotonin Receptor Agonists; Stereotyped Behavior; Syndrome | 2000 |
Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.
Topics: Acoustic Stimulation; Adamantane; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Conditioning, Classical; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Female; Haloperidol; Imidazoles; Inhibition, Psychological; Neurotensin; Photic Stimulation; Psychomotor Performance; Quetiapine Fumarate; Rats; Rats, Long-Evans; Reaction Time; Receptors, Neurotensin; Reflex, Startle; RNA, Messenger; Schizophrenia; Social Isolation; Synaptic Transmission | 2001 |
Biperiden hydrochlorate ameliorates dystonia of rats produced by microinjection of sigma ligands into the red nucleus.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Biperiden; Disease Models, Animal; Guanidines; Haloperidol; Male; Muscarinic Antagonists; Neuroleptic Malignant Syndrome; Rats; Rats, Wistar; Receptors, sigma; Red Nucleus; Torticollis | 2000 |
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Benzimidazoles; Bromocriptine; Cimetidine; Disease Models, Animal; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Indomethacin; Lansoprazole; Male; Mice; Mice, Inbred Strains; Misoprostol; Omeprazole; Pantoprazole; Peptide Fragments; Proteins; Ranitidine; Stomach Diseases; Sulfoxides | 2001 |
Atypical antipsychotic effects of quetiapine fumarate in animal models.
Topics: Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Disease Models, Animal; Female; Haloperidol; Immobilization; Male; Mice; Phencyclidine; Rats; Rats, Wistar; Schizophrenia; Schizophrenia, Paranoid | 2000 |
Role of the central nervous system in hemopoiesis regulation during experimental neuroses.
Topics: Animals; Brain Chemistry; Central Nervous System; Conflict, Psychological; Cyproheptadine; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Hematopoiesis; Hematopoietic Stem Cells; Mice; Mice, Inbred CBA; Neurotic Disorders; Serotonin Antagonists; Sleep Deprivation | 2001 |
An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Haloperidol; Male; Muscle Rigidity; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Substantia Nigra; Thioridazine | 2001 |
Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43.
Topics: Amphetamine; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Drug Administration Schedule; Excitatory Amino Acid Antagonists; GAP-43 Protein; Haloperidol; Male; Neostriatum; Neurons; Phencyclidine; Psychoses, Substance-Induced; Psychotic Disorders; Rats; Rats, Inbred Strains; RNA, Messenger | 2001 |
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine; Haloperidol; Male; Microinjections; Muscle Rigidity; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Tarsus, Animal | 2001 |
Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepinones; Central Nervous System Stimulants; Clozapine; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Locomotion; Male; Pyridines; Rats; Rats, Wistar; Reflex, Startle; Schizophrenia | 2001 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bromocriptine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Fear; Fluvoxamine; Haloperidol; Indophenol; Male; Maze Learning; Mecamylamine; Mice; Mice, Inbred ICR; Moclobemide; Motor Activity; Nicotine; Nicotinic Antagonists; Nortriptyline; Physostigmine; Picolinic Acids; Pyrrolidinones; Serotonin Antagonists; Serotonin Receptor Agonists; Social Behavior; Stress, Psychological | 2001 |
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal; Haloperidol; Male; Niacin; Nicotine; Rats; Rats, Sprague-Dawley; Schizophrenia; Vasodilation | 2001 |
Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG/Rij rats.
Topics: Action Potentials; Animals; Apomorphine; Biological Clocks; Cerebral Cortex; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Electroencephalography; Epilepsy, Absence; Haloperidol; Neurons; Rats; Rats, Mutant Strains | 2001 |
The protective effect of hypervolemic hemodilution in experimental heatstroke.
Topics: Analysis of Variance; Animals; Body Temperature; Carbon Dioxide; Corpus Striatum; Disease Models, Animal; Haloperidol; Heat Stroke; Hemodilution; Monitoring, Physiologic; Neurons; Oxygen; Partial Pressure; Rats; Rats, Wistar; Regional Blood Flow; Survival Rate; Time Factors | 2001 |
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blepharoptosis; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Immobilization; Male; Mice; Mice, Knockout; Motor Activity; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Receptors, Purinergic P1; Reserpine; Swimming; Time Factors; Triazoles | 2001 |
Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
Topics: Animals; Anti-Dyskinesia Agents; Central Nervous System Stimulants; Corpus Callosum; Corpus Striatum; Disease Models, Animal; DNA-Binding Proteins; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Early Growth Response Protein 1; Gene Expression; Genes, Immediate-Early; Glial Fibrillary Acidic Protein; Haloperidol; Huntington Disease; Immediate-Early Proteins; Methamphetamine; Mice; Mice, Transgenic; Nerve Tissue Proteins; Phosphoproteins; Proto-Oncogene Proteins c-fos; Quinolinic Acid; RNA, Messenger; Transcription Factors | 2002 |
Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Antioxidants; Disease Models, Animal; Dyskinesia, Drug-Induced; Ergosterol; Glycosides; Haloperidol; Male; Phytotherapy; Plant Extracts; Plant Roots; Rats; Rats, Wistar; Sitosterols; Solanaceae; Valproic Acid; Vitamin E; Withanolides | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hippocampus; Male; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Reflex, Startle; Reserpine; Schizophrenia | 2002 |
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Hypertrophy; Male; Neostriatum; Neuronal Plasticity; Neurons; Putamen; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Time Factors | 2002 |
[An experimental study of the spectrum of individual psychotropic activity of clozapine (Leponex)].
Topics: Animals; Antipsychotic Agents; Cats; Clozapine; Diazepam; Dibenzazepines; Disease Models, Animal; Haloperidol; Humans; Mental Disorders; Neurotic Disorders; Psychotic Disorders; Social Behavior; Tranquilizing Agents | 1975 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Huntington Disease; Hydrazines; Levodopa; Male; Phentolamine; Rats; Trifluoperazine; Tyramine | 1976 |
Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Benserazide; Callitrichinae; Disease Models, Animal; Drug Therapy, Combination; Haloperidol; Haplorhini; Hydroxydopamines; Hypothalamus; Levodopa; Locus Coeruleus; Male; Torticollis | 1979 |
Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia.
Topics: Animals; Attention; Avoidance Learning; Behavior; Chlorpromazine; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; Humans; Motor Activity; N,N-Dimethyltryptamine; Pargyline; Phenethylamines; Rats; Schizophrenic Psychology; Stereotyped Behavior; Time Factors; Tryptamines | 1978 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Papio; Parasympatholytics; Physostigmine; Pimozide; Receptors, Dopamine; Reserpine; Syndrome; Tranquilizing Agents | 1977 |
Dyskinesias evoked in monkeys by weekly administration of haloperidol.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Haplorhini; Time Factors | 1978 |
Clinical and experimental studies of phenytoin-induced hyperkinesias.
Topics: Aged; Animals; Apomorphine; Basal Ganglia; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Haloperidol; Humans; Hyperkinesis; Male; Middle Aged; Phenytoin; Stereotyped Behavior | 1979 |
Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia?
Topics: Animals; Behavior; Dextroamphetamine; Disease Models, Animal; Haloperidol; Humans; Male; Phenethylamines; Pimozide; Rats; Schizophrenia; Stereotyped Behavior; Time Factors | 1977 |
Choline chloride in animal models of tardive dyskinesia.
Topics: Animals; Apomorphine; Choline; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Rats; Receptors, Dopamine; Stereotyped Behavior; Time Factors | 1978 |
The effect of lithium on an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Humans; Lithium; Male; Receptors, Dopamine; Stereotyped Behavior | 1977 |
[Pathogenesis of stereotyped behavior].
Topics: Animals; Behavior; Caudate Nucleus; Diazepam; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Humans; Lithium; Penicillins; Picrotoxin; Rats; Schizophrenia; Stereotyped Behavior; Syndrome; Tetanus Toxin | 1979 |
Striatal membrane 3H-dopamine binding in an animal model of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol | 1978 |
Effect of centrally acting drugs on experimental torticollis in monkeys.
Topics: Acetates; Alkaloids; Aminooxyacetic Acid; Animals; Brain Stem; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; Electromyography; Haloperidol; Haplorhini; Harmaline; Humans; Levodopa; Macaca mulatta; Methyltyrosines; Muscle Tonus; Pimozide; Tegmentum Mesencephali; Torticollis | 1976 |
Haloperidol-induced tardive dyskinesia in monkeys.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Haplorhini; Macaca fascicularis; Male; Movement Disorders; Muscle Tonus; Parkinson Disease, Secondary; Time Factors | 1976 |
Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; Disease Models, Animal; Dopamine; Drug Tolerance; Female; Haloperidol; Homovanillic Acid; Humans; Loxapine; Male; Movement Disorders; Rats; Receptors, Drug; Stereotyped Behavior; Substance Withdrawal Syndrome | 1975 |
Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Methyltyrosines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Time Factors | 1992 |
Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow.
Topics: Animals; Blood Flow Velocity; Bromocriptine; Disease Models, Animal; Domperidone; Dopamine Antagonists; Eye; Haloperidol; Intraocular Pressure; Ocular Hypertension; Rabbits | 1992 |
Effects of haloperidol, bromocriptine and amphetamine on the development of Ehrlich ascites carcinoma in mice.
Topics: Amphetamine; Analysis of Variance; Animals; Bromocriptine; Carcinoma, Ehrlich Tumor; Disease Models, Animal; Haloperidol; Male; Mice; Neoplasm Transplantation; Random Allocation | 1992 |
Mapping of cerebral energy metabolism in rats with genetic generalized nonconvulsive epilepsy.
Topics: Animals; Brain; Brain Mapping; Disease Models, Animal; Electroencephalography; Energy Metabolism; Epilepsy, Absence; Ethosuximide; Glucose; Haloperidol; Male; Rats; Rats, Inbred Strains; Reference Values | 1992 |
Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Mastication; Rats; Rats, Inbred Strains | 1992 |
Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced mov
Topics: Animals; Clozapine; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalin, Methionine; Globus Pallidus; Haloperidol; Immunoenzyme Techniques; Immunohistochemistry; Male; Models, Neurological; Organ Specificity; Rats; Rats, Inbred Strains; Water | 1992 |
Inhibition by thyrotropin-releasing hormone of epileptic seizures in spontaneously epileptic rats.
Topics: Animals; Disease Models, Animal; Electrodes; Electroencephalography; Epilepsy; Female; Haloperidol; Male; Rats; Rats, Inbred Strains; Thyrotropin-Releasing Hormone | 1991 |
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Topics: Animals; Antipsychotic Agents; Arousal; Benzamides; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Male; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D2; Remoxipride | 1990 |
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Emetics; Haloperidol; Ipecac; Male; Nausea; Oxotremorine; Saimiri; Stereotyped Behavior | 1990 |
Differential modulation of mouse brain biogenic amines by haloperidol and pimozide: implications in Tourette's syndrome.
Topics: Animals; Biogenic Amines; Brain; Disease Models, Animal; Haloperidol; Humans; Male; Mice; Mice, Inbred Strains; Motor Activity; Normetanephrine; Organ Specificity; Pimozide; Reference Values; Tourette Syndrome | 1990 |
Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Topics: Animals; Antipsychotic Agents; Atropine; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Mastication; Rats; Rats, Inbred Strains; Time Factors | 1990 |
The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.
Topics: Animals; Appetitive Behavior; Arousal; Association Learning; Attention; Brain; Conditioning, Classical; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Humans; Inhibition, Psychological; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Schizophrenic Psychology; Sulpiride | 1991 |
Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior.
Topics: Animals; Arousal; Chlorpromazine; Conditioning, Classical; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Methamphetamine; Motor Activity; Neurocognitive Disorders; Orientation; Pimozide; Rats; Rats, Inbred Strains; Schizophrenic Psychology; Stereotyped Behavior | 1990 |
Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat.
Topics: Animals; Catheterization; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Humans; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mastication; Movement; Pilocarpine; Rats; Rats, Inbred Strains; Scopolamine; Tongue | 1990 |
Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome?
Topics: Animals; Brain; Bromocriptine; Disease Models, Animal; Haloperidol; Halothane; Hyperthermia, Induced; Lithium; Lithium Carbonate; Neuroleptic Malignant Syndrome; Pilot Projects; Receptors, Dopamine; Swine; Swine Diseases | 1990 |
Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
Topics: Animals; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Facial Expression; Facial Muscles; Haloperidol; Macaca fascicularis; Mastication; Movement Disorders; Physostigmine; Scopolamine; Stereotyped Behavior | 1990 |
Is experimental catalepsy properly measured?
Topics: Adrenal Glands; Animals; Apomorphine; Catalepsy; Disease Models, Animal; Drug Interactions; Haloperidol; Male; Rats; Rats, Inbred Strains | 1990 |
A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat.
Topics: Animals; Atropine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Parkinson Disease, Secondary; Proprioception; Psychomotor Performance; Rats; Rats, Inbred Strains; Tremor | 1990 |
Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Body Weight; Clozapine; Dibenzazepines; Disease Models, Animal; Drinking; Dyskinesia, Drug-Induced; Female; Fourier Analysis; Haloperidol; Raclopride; Rats; Rats, Inbred Strains; Salicylamides | 1990 |
Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
Topics: Animals; Autoradiography; Behavior, Animal; Benzazepines; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA-A; Spiperone | 1989 |
Ketamine-induced tongue protrusions in rats.
Topics: Animals; Deglutition; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Hypoglossal Nerve; Ketamine; Rats; Rats, Inbred Strains; Tongue | 1989 |
[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Topics: Animals; Catalepsy; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Mouth Diseases; Psychotropic Drugs; Rats; Rats, Inbred Strains | 1989 |
The pathophysiology of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluphenazine; Guinea Pigs; Haloperidol; Humans; Receptors, Dopamine; Stereotyped Behavior; Thioridazine; Time Factors | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Fluphenazine; Frontal Lobe; gamma-Aminobutyric Acid; Globus Pallidus; Glutamate Decarboxylase; Haloperidol; Homovanillic Acid; Rats; Substantia Nigra | 1985 |
Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Topics: Animals; Antipsychotic Agents; Benztropine; Cebus; Death, Sudden; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Macaca; Male; Motor Activity; Stereotyped Behavior; Substance Withdrawal Syndrome | 1985 |
Haloperidol-induced emotional defecation: a possible model for neuroleptic anxiety syndrome.
Topics: Animals; Antipsychotic Agents; Anxiety; Corpus Striatum; Defecation; Digestive System; Disease Models, Animal; Eliminative Behavior, Animal; Haloperidol; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Syndrome | 1987 |
[The influences of neurotransmitters on the traumatic unconsciousness, immediate convulsion and mortality in the experimental mice model].
Topics: Animals; Atropine; Craniocerebral Trauma; Disease Models, Animal; Haloperidol; Male; Methamphetamine; Mice; Neurotransmitter Agents; Physostigmine; Scopolamine; Seizures; Unconsciousness | 1987 |
Enhancement by haloperidol of the locomotor response induced by naloxone in morphine-treated guinea pigs.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Guinea Pigs; Haloperidol; Male; Morphine; Motor Activity; Naloxone; Substance Withdrawal Syndrome; Time Factors | 1989 |
The effects of carbamazepine on two animal models of depression.
Topics: Animals; Carbamazepine; Depressive Disorder; Disease Models, Animal; Haloperidol; Imipramine; Male; Methamphetamine; Motivation; Motor Activity; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1987 |
L-5-HTP-induced myoclonic jumping behavior in guinea pigs: an update.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Bromocriptine; Clonazepam; Disease Models, Animal; Guinea Pigs; Haloperidol; Lisuride; Morphine; Myoclonus; Naloxone; Scopolamine; Tremorine | 1986 |
Animal models for schizophrenia: the hippocampally lesioned animal.
Topics: Animals; Attention; Disease Models, Animal; Dopamine Antagonists; Galvanic Skin Response; Haloperidol; Hippocampus; Humans; Learning; Memory; Schizophrenia; Schizophrenic Psychology; Space Perception; Stereotyped Behavior | 1987 |
Head displacement and bracing in haloperidol-treated rats compared to rats with lateral hypothalamic damage.
Topics: Animals; Brain Diseases; Catalepsy; Disease Models, Animal; Haloperidol; Hydroxydopamines; Hypothalamic Area, Lateral; Male; Methysergide; Motor Activity; Oxidopamine; Rats; Reflex | 1985 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal Lobe; Haloperidol; Haplorhini; Levodopa; Mesencephalon; Methyltyrosines; Mice; Movement Disorders; Parkinson Disease; Posture; Rats; Reserpine; Substantia Nigra; Tegmentum Mesencephali; Thalamic Nuclei; Tremor | 1974 |
Rigidity and tremor induced in feline muscles deprived of their fusiomtor control.
Topics: Achilles Tendon; Animals; Animals, Newborn; Cats; Disease Models, Animal; Electromyography; Haloperidol; Muscle Contraction; Muscle Rigidity; Muscle Spindles; Muscles; Neural Conduction; Neurons, Afferent; Parkinson Disease; Sciatic Nerve; Tremor | 1974 |
Studies in experimental spinal cord trauma. 2. Comparison of treatment with steroids, low molecular weight dextran, and catecholamine blockade.
Topics: Animals; Dextrans; Disease Models, Animal; Dogs; Edema; Glucocorticoids; Haloperidol; Hypoxia; Methyltyrosines; Necrosis; Paraplegia; Phenoxybenzamine; Spinal Cord; Spinal Cord Injuries | 1974 |
A Stretchable and Transparent Electrode Based on PEGylated Silk Fibroin for In Vivo Dual-Modal Neural-Vascular Activity Probing.
Topics: Animals; Brain-Computer Interfaces; Disease Models, Animal; Elastic Modulus; Electric Conductivity; Electrodes; Electrodes, Implanted; Electronics; Electrophysiology; Epoxy Resins; Fibroins; Hydrogels; Polystyrenes; Pressure; Rats; Silk; Spectroscopy, Fourier Transform Infrared; Stress, Mechanical; Stroke; Thiophenes | 2021 |
Evaluation of Inflammatory Response to Endodontic Sealers in a Bone Defect Animal Model.
Topics: Aluminum Compounds; Animals; Biocompatible Materials; Calcium Compounds; Disease Models, Animal; Drug Combinations; Epoxy Resins; Mandible; Materials Testing; Oxides; Rats, Wistar; Root Canal Filling Materials; Silicates | 2016 |
Cholangiocytes of cirrhotic rats are more tolerant to ischemia than normal rats: a role for abnormal hepatic arteriovenous communications?
Topics: Animals; Apoptosis; Arteriovenous Fistula; Bile Ducts; Blood Circulation; Disease Models, Animal; Epoxy Resins; Hypoxia-Inducible Factor 1; Ischemia; Liver; Liver Cirrhosis; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A | 2011 |
A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset.
Topics: Animals; Behavior, Animal; Brain; Callithrix; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Epoxy Resins; Female; Forelimb; Hand Strength; Hindlimb; Infarction, Middle Cerebral Artery; Male; Perfusion; Phthalic Anhydrides; Physical Stimulation; Pilot Projects; Reflex; Reperfusion Injury; Reward; Stroke; Vocalization, Animal | 2004 |
The effect of intracanal anti-inflammatory medicaments on external root resorption of replanted dog teeth after extended extra-oral dry time.
Topics: Animals; Anti-Inflammatory Agents; Demeclocycline; Dental Alloys; Desiccation; Disease Models, Animal; Dogs; Drug Combinations; Edetic Acid; Epoxy Resins; Glucocorticoids; Gutta-Percha; Nickel; Root Canal Filling Materials; Root Canal Irrigants; Root Canal Preparation; Root Resorption; Sodium Hypochlorite; Time Factors; Titanium; Tooth Avulsion; Tooth Replantation; Triamcinolone Acetonide; Wound Healing | 2008 |
Heparinization on pericardial substitutes can reduce adhesion and epicardial inflammation in the dog.
Topics: Animals; Anticoagulants; Biocompatible Materials; Disease Models, Animal; Dogs; Epoxy Resins; Follow-Up Studies; Glutaral; Heparin; Membranes, Artificial; Pericarditis; Pericardium; Polyethylene Terephthalates; Polytetrafluoroethylene; Prosthesis Implantation; Swine; Tissue Adhesions; Tissue Fixation; Transplantation, Heterologous | 1998 |
Allergenicity of epoxy resins in the guinea pig.
Topics: Allergens; Animals; Dermatitis, Contact; Disease Models, Animal; Epichlorohydrin; Epoxy Resins; Female; Guinea Pigs; Immunization; Molecular Weight; Propane | 1977 |
Picroside III, an Active Ingredient of Picrorhiza scrophulariiflora, Ameliorates Experimental Colitis by Protecting Intestinal Barrier Integrity.
Topics: AMP-Activated Protein Kinases; Animals; Caco-2 Cells; Claudin-2; Claudin-3; Colitis; Disease Models, Animal; Humans; Intestinal Mucosa; Mice; Occludin; Picrorhiza; Tumor Necrosis Factor-alpha | 2023 |